9/995,177

L Number	Hits	Search Text	DB	Time stamp
1	34890	propionic adj acid	USPAT; US-PGPUB	2002/05/15 20:59
3	0	aza adj1 indacen$	USPAT; US-PGPUB	2002/05/15 21:01
4	422	indacen$	USPAT; US-PGPUB	2002/05/15 21:02
2	2	triaza adj anthracen$	USPAT; US-PGPUB	2002/05/15 21:02
5	77	(propionic adj acid) and indacen$	USPAT; US-PGPUB	2002/05/15 21:03

09/ 995,177

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Jan 25	BLAST(R) searching in REGISTRY available in STN on the Web
NEWS	3	Jan 29	FSTA has been reloaded and moves to weekly updates
NEWS	4	Feb 01	DKILIT now produced by FIZ Karlsruhe and has a new update frequency
NEWS	5	Feb 19	Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS	6	Mar 08	Gene Names now available in BIOSIS
NEWS	7	Mar 22	TOXLIT no longer available
NEWS	8	Mar 22	TRCTHERMO no longer available
NEWS	9	Mar 28	US Provisional Priorities searched with P in CA/CAplus and USPATFULL
NEWS	10	Mar 28	LIPINSKI/CALC added for property searching in REGISTRY
NEWS	11	Apr 02	PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS	12	Apr 08	"Ask CAS" for self-help around the clock
NEWS	13	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	14	Apr 09	ZDB will be removed from STN
NEWS	15	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	16	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	17	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	18	Apr 22	Federal Research in Progress (FEDRIP) now available

NEWS EXPRESS	February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:49:06 ON 09 MAY 2002

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

09/ 995,177

FILE 'REGISTRY' ENTERED AT 15:49:14 ON 09 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 7 MAY 2002 HIGHEST RN 412267-09-5
DICTIONARY FILE UPDATES: 7 MAY 2002 HIGHEST RN 412267-09-5

TSCA INFORMATION NOW CURRENT THROUGH July 7, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09995177.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 H,O

G2 O,S,N,SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 15:49:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 20299 TO ITERATE

4.9% PROCESSED 1000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 397477 TO 414483
PROJECTED ANSWERS: 1083 TO 2163

L2 4 SEA SSS SAM L1

=> s l1 ful

09/ 995,177

FULL SEARCH INITIATED 15:49:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 405697 TO ITERATE

98.6% PROCESSED 400000 ITERATIONS 742 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.14

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 405697 TO 405697
PROJECTED ANSWERS: 742 TO 834

L3 742 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.66	140.87

FILE 'CAPLUS' ENTERED AT 15:50:11 ON 09 MAY 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 9 May 2002 VOL 136 ISS 19
FILE LAST UPDATED: 7 May 2002 (20020507/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l3
L4 140 L3

=> s l4 and propion?
92817 PROPION?
L5 6 L4 AND PROPION?

=> d l5 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:142668 CAPLUS
DOCUMENT NUMBER: 136:183704
TITLE: Indoline derivatives as 5-HT2C antagonists, useful as anxiolytics and antidepressants
INVENTOR(S): Bromidge, Steven Mark; Lovell, Peter John; Moss, Stephen Frederick; Serafinowska, Halina Teresa

09/ 995,177

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014273	A1	20020221	WO 2001-EP9273	20010809

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2000-19950 A 20000812
OTHER SOURCE(S): MARPAT 136:183704
GI



I



II

AB The invention relates to novel cinnamide compds., which have 5-HT2C antagonist activity, of formula I, or pharmaceutically acceptable salts thereof [in which: ring Q is Ph or naphthyl; R1 is halo, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, OH, (di)(C1-6alkyl)amino, NO2, CN, CF3, OCF3, aryl, arylC1-6alkyl, arylC1-6alkyloxy or arylC1-6alkylthio; m is 0-5; R2 and R3 are independently H or C1-6alkyl; R4 is H, halo, C1-6alkyl, C1-6alkoxy, aryl, cyano, haloC1-6alkyl or OCF3; Z is C or N; R5 is either: (i) a group NR6R7 where R6 and R7 are independently H, (un)substituted C1-6alkyl; or (ii) (un)substituted N-linked heterocycle; or (iii) an (un)substituted C-linked heterocycle; n = 0-3, provided that n in not 0 when R5 is a group (i) or (ii); dashed line is an optional double bond, where X and Y are independently CR8R9 (when single bond) or CR10 (when double bond); wherein R8, R9 and R10 are independently H or C1-6alkyl]. Also disclosed are processes for prepn. of I, compns. contg. them, and

their use in the treatment of CNS and other disorders. In particular, their use for treating anxiety and/or depression is claimed. A total of 171 examples and 73 intermediate prepns. are given. For instance, 2-methoxy-5-nitrophenol was etherified with 1-(2-chloroethyl)piperidine-HCl (70%), followed by hydrogenation of nitro to amino (100%), reductive alkylation of amino with (MeO)2CHCHO (88%), cyclization to form an indole (73%), redn. to give an indoline (72%), and N-coupling with 2-chlorocinnamic acid (40%), to give preferred (as HCl salt) invention compd. (E)-II. In a test for inhibition of[3H]-mesulergine binding at human 5-HT2C clones expressed in HEK 293 cells in vitro, I had pKi values in the range of 7.5-9.8.

IT **399579-52-3P**, (E)-1-[6-[2-(8-Azabicyclo[3.2.1]oct-8-yl)ethoxy]-5-methoxy-2,3-dihydroindol-1-yl]-3-(2-chlorophenyl)prop-2-en-1-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of indoline derivs. as 5-HT2C antagonists)

RN 399579-52-3 CAPLUS

CN 1H-Indole, 6-[2-(8-azabicyclo[3.2.1]oct-8-yl)ethoxy]-1-[(2E)-3-(2-chlorophenyl)-1-oxo-2-propenyl]-2,3-dihydro-5-methoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:338355 CAPLUS
DOCUMENT NUMBER: 134:340509
TITLE: Preparation of 8-azabicyclo[3.2.1]octane NMDA/NR2B antagonists
INVENTOR(S): Thompson, Wayne; Claremon, David A.; Munson, Peter M.; Phillips, Brian
PATENT ASSIGNEE(S): Merck + Co., Inc., USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032179	A1	20010510	WO 2000-US29479	20001026

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,

ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 1999-162718P P 19991029
OTHER SOURCE(S): MARPAT 134:340509
GI



I



II

AB The title compds., commonly known as tropanes, (I) [wherein R1 = (un)substituted 2-benzimidazole, imidazole, imidazopyridine, indole, quinazoline, purine, benzoxazolone, or phenol; R2 = Ph, optionally substituted with 1-5 substituents selected from Cl, F, Br, alkyl, CF3, OH, or CO2H; L1 and L2 = independently (cyclo)alkyl, alkenyl, alkynyl, alkoxy, aminoalkyl, hydroxyalkyl, or (amino)carbonyl; X = OH, NH2, (di)alkylamino, alkyl, ester, carbamate, carbonate, or ether] were prepd. as effective NMDA NR2B glutamate receptor antagonists. For example, addn. of di-Et 4-chlorobenzylphosphonate to N-carbethoxy-4-tropinone to give the benzylidene, redn. using Pt/C, N-deprotection using HBr in AcOH, and reductive addn. of 1-(trimethylsilylethoxymethyl)-1H-benzimidazole-2-carbaldehyde (2-step prepn. given) using NaBH(OAc)3 in ClCH2CH2Cl afforded exo-II. Exptl. protocols for assessing the inhibition of NR1A/2B NMDA receptor activation (FLIPR assay) and detg. the apparent dissocn. consts. against the human NR1A/NR2B receptor (binding assay) are given (no data). I are useful for relieving pain and treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke (no data).

IT **338732-87-9P 338732-88-0P 338733-14-5P 338733-15-6P 338795-48-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (benzimidazolylalkyl)tropane NMDA/NR2B antagonists for treatment of pain)

RN 338732-87-9 CAPLUS

CN Phenol, 4-[2-[(3-exo)-3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 338732-88-0 CAPLUS
CN Phenol, 4-[2-[(3-exo)-3-[(4-chlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 338733-14-5 CAPLUS
CN Phenol, 4-[2-[3-(phenylmethyl)-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]- (9CI) (CA INDEX NAME)



RN 338733-15-6 CAPLUS
CN Phenol, 4-[2-[3-[(4-chlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]- (9CI) (CA INDEX NAME)



RN 338795-48-5 CAPLUS
CN Phenol, 4-[2-[(3-endo)-3-[(4-chlorophenyl)methyl]-8-azabicyclo[3.2.1]oct-8-yl]ethoxy]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:277964 CAPLUS
DOCUMENT NUMBER: 132:308362
TITLE: Preparation of tricyclic compounds for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR)
INVENTOR(S): Jeppesen, Lone; Bury, Paul Stanley; Sauerberg, Per
PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.; Reddy's Research Foundation
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Applicant's

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023425	A1	20000427	WO 1999-DK570	19991019
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9961902	A1	20000508	AU 1999-61902	19991019
EP 1123279	A1	20010816	EP 1999-948738	19991019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: DK 1998-1352 A 19981021
WO 1999-DK570 W 19991019
OTHER SOURCE(S): MARPAT 132:308362
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1-R4 = H, halo, perhalomethyl, etc.; R1 and R2, R2 and R3, R3 and R4 may form (un)substituted cyclic ring contg. 5-7 carbon atoms; A = (un)substituted 5-6 membered cyclic ring; X = a bond, CH:CH, OCH2O, etc.; Ar = (un)substituted arylene, heteroarylene, divalent heterocyclic group; R5 = H, OH, halo, etc.; R6 = H, OH, halo, etc.; R7 = H, alkyl, alkenyl, etc.; R8 = H, alkyl, alkenyl, etc.; Y = O, S, NH, etc.; n = 1-4; m = 0-1], useful in the treatment and/or prevention of conditions

mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR) (e.g., in the treatment of diabetes and/or obesity), were prepd. and formulated. Thus, reacting 2-(10,11-dihydrodibenzo[b,f]azepin-5-yl)ethanol with Et 2-ethoxy-3-(4-hydroxyphenyl)**propionate** in the presence of triphenylphosphine and di-Et azodicarboxylate afforded 90% II. Compds. I are effective at 0.1-70 mg/day in the treatment of adult humans.

IT **265302-51-0P 265302-53-2P 265302-55-4P**
265302-57-6P 265302-59-8P 265302-61-2P
265302-63-4P 265302-65-6P 265302-66-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tricyclic compds. for the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR))

RN 265302-51-0 CAPLUS
CN Benzenepropanoic acid, .alpha.-ethoxy-4-[2-(9-oxo-10(9H)-acridinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 265302-53-2 CAPLUS
CN Benzenepropanoic acid, .alpha.-methoxy-4-[2-(9-oxo-10(9H)-acridinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 265302-55-4 CAPLUS
CN Benzenepropanoic acid, 4-[2-(9-oxo-10(9H)-acridinyl)ethoxy]-.alpha.-propoxy- (9CI) (CA INDEX NAME)



RN 265302-57-6 CAPLUS
CN Benzenepropanoic acid, 4-[2-(9-oxo-10(9H)-acridinyl)ethoxy]-.alpha.-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 265302-59-8 CAPLUS
CN Benzenepropanoic acid, .alpha.-ethoxy-4-[(9-oxo-10(9H)-acridinyl)methoxy]- (9CI) (CA INDEX NAME)



RN 265302-61-2 CAPLUS
CN Benzenepropanoic acid, .alpha.-ethoxy-4-[3-(9-oxo-10(9H)-acridinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 265302-63-4 CAPLUS
CN Benzenepropanoic acid, 4-[3-(9-oxo-10(9H)-acridinyl)propoxy]-.alpha.-propoxy- (9CI) (CA INDEX NAME)



RN 265302-65-6 CAPLUS
CN Benzenepropanoic acid, .alpha.-methoxy-4-[3-(9-oxo-10(9H)-acridinyl)propoxy]- (9CI) (CA INDEX NAME)



RN 265302-66-7 CAPLUS
CN Benzenepropanoic acid, 4-[3-(9-oxo-10(9H)-acridinyl)propoxy]-.alpha.-(phenylmethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:475118 CAPLUS
DOCUMENT NUMBER: 127:199374
TITLE: Methods of sensing with fluorescent conjugates of metal-chelating nitrogen heterocycles
INVENTOR(S): Kuhn, Michael A.; Haugland, Richard P.; Hoyland, Brian Matthew
PATENT ASSIGNEE(S): Molecular Probes, Inc., USA
SOURCE: U.S., 25 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English

09/ 995,177

FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5648270	A	19970715	US 1995-384945	19950206
US 5723218	A	19980303	US 1995-484151	19950607
US 6013802	A	20000111	US 1997-798390	19970207

PRIORITY APPLN. INFO.:

US 1990-509360 19900416
US 1990-629466 19901218
US 1991-786767 19911101
US 1992-843360 19920225
US 1992-882299 19920513
US 1993-28319 19930308
US 1993-38918 19930329
US 1993-45758 19930408
US 1994-246790 19940520
US 1994-246847 19940520
US 1994-247013 19940520
US 1994-247108 19940520
US 1995-375360 19950119
US 1995-384945 19950206

OTHER SOURCE(S): MARPAT 127:199374

AB The present invention describes the use of a family of fluorescent indicators for metal cations. The indicators are fluorophore conjugates of pyridyl-based metal ion chelators. The indicators are very sensitive detection as quantification reagents for a variety of metals, in a variety of oxidn. states, even in the presence of high concns. of Ca2+, Na+, or K+ or other ions, such as is found in seawater, making them highly useful for assaying physiol. samples, biol. samples, or environmental samples.

IT **194143-73-2P**
RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)
(metal cations detn. in physiol. or biol. or environmental samples in presence of Ca2+, Na+, or K+ by fluorometry using fluorescent indicators based on fluorescent conjugates of metal-chelating nitrogen heterocycles)

RN 194143-73-2 CAPLUS
CN 10(9H)-Acridineacetamide, 9-oxo-N-1,10-phenanthrolin-5-yl- (9CI) (CA INDEX NAME)



L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1994:680471 CAPLUS
DOCUMENT NUMBER: 121:280471
TITLE: Preparation of dynemicin analogs as bactericides and antitumor agents
INVENTOR(S): Smith, Adrian L.; Hwang, Chan Kou; Wenderborn, Sebastian V.; Nicolaou, Kyriacos C.; Schreiner, Erwin P.; Stahl, Wilhelm; Dai, Wei Min; Maligres, Peter E.; Suzuki, Toshio
PATENT ASSIGNEE(S): Scripps Research Institute, USA
SOURCE: U.S., 114 pp. Cont.-in-part of U.S.Ser. No. 886,984,abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5281710	A	19940125	US 1992-939104	19920901
US 5276159	A	19940104	US 1992-886984	19920521
US 5500432	A	19960319	US 1993-46626	19930414
WO 9323046	A1	19931125	WO 1993-US4708	19930518
W: AU, CA, FI, JP, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9343807	A1	19931213	AU 1993-43807	19930518
AU 680418	B2	19970731		
EP 641207	A1	19950308	EP 1993-913966	19930518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07508037	T2	19950907	JP 1993-503816	19930518
US 5527805	A	19960618	US 1994-184580	19940121
FI 9405427	A	19950118	FI 1994-5427	19941118
NO 9404429	A	19950123	NO 1994-4429	19941118

PRIORITY APPLN. INFO.:
US 1990-562269 19900801
US 1991-673199 19910321
US 1991-734613 19910723
US 1991-788225 19911105
US 1992-886984 19920521
US 1992-939104 19920901
WO 1993-US4708 19930518

OTHER SOURCE(S): MARPAT 121:280471
GI



AB The title compds. I [A = double or single bond; R1 = H, alkyl, phenoxycarbonyl, etc.; R2 = H, carboxyl, hydroxylmethyl, etc.; R3 = H,

alkoxy; R4 = H, hydroxyl, alkoxy, etc.; R6 and R7 are each H or together with the intervening vinylene group form a one, two or three fused arom. six-membered ring system; W together with the bonded, intervening, vinylene group (i.e., the unsatd. carbon atoms bonded to W) forms a substituted arom. hydrocarbyl ring system contg. 1, 2, or 3 six-membered rings such that said fused ring compd. contains 3, 4, or 5 fused 6-membered rings all but two of which rings are arom., and in which that arom. hydrocarbyl ring system, W, is joined [a,b] to the structure shown; R8 = H, or Me; a proviso is given] are prepd. Title compd. II (X = OH) (prepn. given) in vitro exhibited IC50 of 6.3 x 10-6 M against a variety of cancer cell lines. II (X = H) in vitro exhibited IC50 of 5.0 x 10-6 M against a variety of cancer cell lines.

IT **130012-98-5P 144154-93-8P 158805-84-6P**
158805-98-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, in prepn. of bactericide and antitumor agent)

RN 130012-98-5 CAPLUS
CN 11,6,12-[1]Butanyl[4]ylidenedibenz[b,f]azocine-5(6H)-carboxylic acid, 11,12-dihydro-12,13-dihydroxy-, phenyl ester, (6.alpha.,11.alpha.,12.beta.,13R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 144154-93-8 CAPLUS
CN 11,6,12-[1]Butanyl[4]ylidenedibenz[b,f]azocine-5(6H)-carboxylic acid, 11,12-dihydro-12,13-dihydroxy-2-(2-hydroxyethoxy)-, phenyl ester, (6.alpha.,11.alpha.,12.beta.,13R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 158805-84-6 CAPLUS
CN 11,6,12-[1]Butanyl[4]ylidenedibenz[b,f]azocine-5(6H)-carboxylic acid, 11-(acetyloxy)-11,12-dihydro-3,12,13-trihydroxy-, phenyl ester, (6.alpha.,11.beta.,12.beta.,13R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 158805-98-2 CAPLUS
CN 11,6,12-[1]Butanyl[4]ylidenedibenz[b,f]azocine-5(6H)-carboxylic acid, 11,12-dihydro-3,11,12,13-tetrahydroxy-, phenyl ester, (6.alpha.,11.beta.,12.beta.,13R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **135106-85-3P 135144-02-4P 144019-98-7P**
144127-87-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 135106-85-3 CAPLUS
CN 11,6,12-[1]Butanyl[4]ylidenedibenz[b,f]azocine-5(6H)-carboxylic acid,
11,12-dihydro-11,12,13-trihydroxy-3-methoxy-, phenyl ester,
(6.alpha.,11.beta.,12.beta.,13R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 135144-02-4 CAPLUS
CN 11,6,12-[1]Butanyl[4]ylidenedibenz[b,f]azocine-5(6H)-carboxylic acid,
12-ethoxy-11,12-dihydro-3,11,13-trihydroxy-, phenyl ester,
(6.alpha.,11.beta.,12.beta.,13R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 144019-98-7 CAPLUS
CN 11,6,12-[1]Butanyl[4]ylidenedibenz[b,f]azocine-5(6H)-carboxylic acid, 11-(acetyloxy)-12-ethoxy-11,12-dihydro-3,13-dihydroxy-, phenyl ester, (6.alpha.,11.beta.,12.beta.,13R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 144127-87-7 CAPLUS
CN 11,6,12-[1]Butanyl[4]ylidenedibenz[b,f]azocine-5(6H)-carboxylic acid, 2-(2,2-dimethyl-1-oxopropoxy)-11,12-dihydro-12,13-dihydroxy-, phenyl ester, (6.alpha.,11.alpha.,12.beta.,13R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **158805-82-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as bactericide and antitumor agent)
RN 158805-82-4 CAPLUS
CN 15,6,16-[1]Butanyl[4]ylideneanthra[2,3-f]benz[b]azocine-5(6H)-carboxylic acid, 15,16-dihydro-15,16,17-trihydroxy-, phenyl ester, (6.alpha.,15.beta.,16.beta.,17R*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 4-E



PAGE 5-A

L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1970:90683 CAPLUS
DOCUMENT NUMBER: 72:90683
TITLE: Chemistry of tropane derivatives. IV. Synthesis of derivatives of nor-(-)-scopolamine, norscopine-(-)-.beta.-chloro-.alpha.-phenylpropionate, and aponorscopolamine
AUTHOR(S): Werner, Gottfried; Schickfluss, Rudolf
CORPORATE SOURCE: Arbeitsgruppe Neurochem., Max-Planck-Inst. Hirnforsch., Frankfurt/M.-Niederrad, Ger.
SOURCE: Justus Liebigs Ann. Chem. (1970), 731, 1-11
CODEN: JLACBF
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Nor-(-)-scopolamines (I) (where R = Et, Pr, Bu, n-C5H11, n-C6H13, AcNH, or PhCH2CH2) were prepd. in 38-77% yield from I (R = H) (Ia) and alkyl halides at .apprx.100.degree. in a sealed tube. Similarly prepd. were N,N'-ethylene-, N,N'-trimethylene-, and N,N'-tetramethylenebis-(nor-(-)-scopolamine) from Ia and the .alpha.,.omega.-dihalo alkanes. Reaction of Ia with epoxides yielded 38-57% I.HCl (where R = HOCH2CH2, HOCHMeCH2, HOCH2CHOHCH2, 1-hydroxy-cyclohexylmethyl, 2-hydroxycyclohexyl, or HOCHPhCH2). Heating (-)-scopolamine (II) with alkyl isocyanates at 100.degree. gave 56-71% of the carbamate-2HCl (III) (where R1 = Me, Et, Pr, or Bu) of II. Reaction of Ia with alkyl isocyanates gave 80% I (where R = MeNHCO, EtNHCO, PrNHCO, or Bu-NHCO). Similarly prepd. were N-(N-phenylcarbamoyl)-, and N-(N-ethylcarbamoyl)aponorscopolamine from aponorscopolamine and alkyl isocyanates. N-(N-Methylcarbamoyl)- and N-(N-ethylcarbamoyl)-(-)-norscopine .beta.-chloro-.alpha.-phenylpropionate were prepd. similarly from (-)-norscopine .alpha.-phenyl-.beta.-chloropropionate.
IT **26516-80-3P 26516-86-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 26516-80-3 CAPLUS
CN Benzeneacetic acid, .alpha.-methylene-, 9-[(phenylamino)carbonyl]-3-oxa-9-

09/ 995,177

azatricyclo[3.3.1.02,4]non-7-yl ester, [7(S)-(1.alpha.,2.beta.,4.beta.,5.a
lpha.,7.beta.)]- (9CI) (CA INDEX NAME)



RN 26516-86-9 CAPLUS
CN 1.alpha.H,5.alpha.H-Nortropane-8-carboxanilide, 6.beta.,7.beta.-epoxy-
3.alpha.-hydroxy- (8CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 15:49:06 ON 09 MAY 2002)

FILE 'REGISTRY' ENTERED AT 15:49:14 ON 09 MAY 2002
L1 STRUCTURE UPLOADED
L2 4 S L1
L3 742 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:50:11 ON 09 MAY 2002
L4 140 S L3
L5 6 S L4 AND PROPION?

=> s l3/biol
140 L3
5093630 BIOL/RL
L6 50 L3/BIOL
(L3 (L) BIOL/RL)

=> s l6 not l5
L7 47 L6 NOT L5

=> d l7 1- ibib abs fhitstr
YOU HAVE REQUESTED DATA FROM 47 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2002:157754 CAPLUS
DOCUMENT NUMBER: 136:216638
TITLE: Aminoalkoxybenzoylbenzofuran or -benzothiophene derivatives for treating pathol. syndromes of the cardiovascular system
INVENTOR(S): Assens, Jean-Louis; Bernhart, Claude; Cabanel-Haudricourt, Frederique; Nisato, Dino

09/ 995,177

PATENT ASSIGNEE(S): Sanofi-Synthelabo Departement Brevets, Fr.
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016340	A1	20020228	WO 2001-FR2657	20010823
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2813308	A1	20020301	FR 2000-10833	20000823

PRIORITY APPLN. INFO.: FR 2000-10833 A 20000823
OTHER SOURCE(S): MARPAT 136:216638
GI



I



II

AB Title compds. I [A = O, S, NHCO; B = alkylene, hydoxyalkylene; T = H, alkyl; R = CN, CH2OH, alkoxyiminomethyl, carboxylic ester, carboxamide, oxadiazolyl, tetrazolyl; R1 = (un)substituted alkyl, cycloalkyl, Ph, CH2Ph; Am = n heterocyclic; X = O, S; Y = CO, CH2, OCH2CH2O, CH(OR3); R3 = H, alkyl, acyl; when W = W1 = CH, Z = O, S; when W = CH, W1 = (un)substituted CH, Z = (un)substituted CH:CH]were prepd. for use as antiarrhythmics, antiadrenergics, and vasodilators. Thus, the benzofuran II was prepd. from 4-HOC6H4CO2Me and BrCHBuCO2H in 9 steps via Me 2-butyl-5-benzofurancarboxylate.

IT **401839-65-4P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(aminoalkoxybenzoylbenzofuran or -benzothiophene derivs. for treating pathol. syndromes of the cardiovascular system)

RN 401839-65-4 CAPLUS

CN 5-Benzofurancarboxylic acid, 3-[4-[2-(9-azabicyclo[3.3.1]non-9-yl)ethoxy]benzoyl]-2-butyl-, methyl ester, ethanedioate (9CI) (CA INDEX NAME)

09/ 995,177

CM 1

CRN 401839-64-3
CMF C31 H37 N O5

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 144-62-7
CMF C2 H2 O4



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:931408 CAPLUS
DOCUMENT NUMBER: 136:216858
TITLE: Synthesis of Cyclopentadienyltricarbonyl Rhenium Phenyltropanes by Double Ligand Transfer: Organometallic Ligands for the Dopamine Transporter
AUTHOR(S): Cesati, Richard R., III; Tamagnan, Gilles; Baldwin, Ronald M.; Zoghbi, Sami S.; Innis, Robert B.; Kula, Nora S.; Baldessarini, Ross J.; Katzenellenbogen, John A.
CORPORATE SOURCE: Department of Chemistry, University of Illinois, Urbana, IL, 61801, USA
SOURCE: Bioconjugate Chemistry (2002), 13(1), 29-39
CODEN: BCCHES; ISSN: 1043-1802
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:216858

AB Cyclopentadienyltricarbonyl rhenium (CpRe(CO)3) systems can be prepd. from ferrocenes and perrhenate by a double ligand transfer (DLT) reaction that gives reasonable yields and shows excellent functional group tolerance. This reaction can be used for the direct prepn. of CpRe(CO)3-phenyltropane conjugates. Such agents, when labeled with technetium-99m, might function as imaging agents for the dopamine transporter (DAT) system that would be useful for assessing the onset and severity of Parkinson's disease. Of the CpRe(CO)3-tropane conjugates prepd. by the DLT reaction (as well as other analogs prepd. by related methods), those substituted at the N-8 position seem most promising; their affinity for the DAT in all cases was high, and their ferrocene precursors for the DLT reaction can be prepd. in a convenient manner. By contrast, the 3.beta.-conjugates were poor DAT binders. The modular nature of these systems offers considerable flexibility that could be used to improve the binding characteristics of these compds. further.

IT **343612-67-9P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation)
(prepn. and affinity for phenyltropane conjugate formation of)
RN 343612-67-9 CAPLUS
CN Rhenium, tricarbonyl[(1,2,3,4,5-.eta.)-rel-1-[4-[(1R,2S,3S,5S)-3-(4-chlorophenyl)-2-(methoxycarbonyl)-8-azabicyclo[3.2.1]oct-8-yl]-1-oxobutoxy]-2,4-cyclopentadien-1-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:472712 CAPLUS
DOCUMENT NUMBER: 135:76800
TITLE: Azabicyclo[3.2.1]octane derivatives with activity as serotonin reuptake inhibitors and 5-HT1A antagonists, and their use as antidepressants.
INVENTOR(S): He, John Xiaoqiang; Honigschmidt, Nicholas Allan; Kohn, Todd Jonathan; Rocco, Vincent Patrick; Spinazze, Patrick Gianpietro; Takeuchi, Kumiko
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046187	A1	20010628	WO 2000-US32431	20001206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-172610P P 19991220
OTHER SOURCE(S): MARPAT 135:76800
GI



I



II

AB The invention provides compds. of formula I [A = H, OH, alkoxy; B = (un)substituted benzothienyl, benzofuranyl, indolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, quinolinyl, phthalazinyl, naphthalenyl, or benzo[h]quinolinyl; X = H, OH, alkoxy, or is absent; Y = CH2, NH, or S; R1 = H, F, alkyl, CONH2 or (di)alkyl derivs., cyano; R2 = H, F, Cl, Br, iodo, OH, alkyl, or alkoxy; p = 0-4; q = 0-3] and their pharmaceutically acceptable salts. The compds. are potent serotonin reuptake inhibitors and antagonists of 5-HT1A receptors (no data). As such, they are expected to be useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. Fourteen synthetic examples and several precursor prepns. are given. For instance, title compd. II was prepd. in 87% yield by reaction of endo-3-(4-methoxybenzo[b]thiophen-2-yl)-8-azabicyclo[3.2.1]octane (prepn. given) with (S)-4-(oxiranylmethoxy)indole in refluxing MeOH.

IT **346465-44-9P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(drug candidate; prepn. of azabicyclooctane derivs. as serotonin reuptake inhibitors and 5-HT1A antagonists for use as antidepressants)

RN 346465-44-9 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-ethanol, .alpha.-[(1H-indol-4-yloxy)methyl]-3-(4-methoxybenzo[b]thien-2-yl)-, (.alpha.S,3-exo)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:472711 CAPLUS
DOCUMENT NUMBER: 135:76778
TITLE: Benzofuran derivatives with activity as serotonin reuptake inhibitors and 5-HT1A antagonists, and their use as antidepressants.
INVENTOR(S): He, John Xiaoqiang; Honigschmidt, Nicholas Allan; Kohn, Todd Jonathan; Rocco, Vincent Patrick; Spinazze, Patrick Gianpietro; Takeuchi, Kumiko
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046186	A1	20010628	WO 2000-US32425	20001206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-172742P P 19991220
OTHER SOURCE(S): MARPAT 135:76778
GI



I



II

AB The invention provides compds. of formula I [A = H, OH, alkoxy; B = (un)substituted benzothienyl, benzofuranyl, indolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, quinolinyl, phthalazinyl, naphthalenyl, or benzo[h]quinolinyl; X = H, OH, alkoxy, or is absent; R, R1 = H, F, alkyl, CONH2 or (di)alkyl derivs., cyano, or R1 is absent; R2 = H, F, Cl, Br, iodo, OH, alkyl, or alkoxy; p = 0-4; q = 0-3] and their pharmaceutically acceptable salts. The compds. are potent serotonin reuptake inhibitors and antagonists of 5-HT1A receptors (no data). As such, they are expected to be useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. Three synthetic examples and several precursor prepns. are given. For instance, title compd. II (as the oxalate) was prepd. in 84% yield by reaction of endo-3-(4-methoxybenzo[b]thiophen-2-yl)-8-azabicyclo[3.2.1]octane (prepn. given) with (2S)-4-(glycidyloxy)benzofuran in refluxing MeOH.

IT **345995-21-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(drug candidate; prepn. of benzofuran derivs. as serotonin reuptake inhibitors and 5-HT1A antagonists for use as antidepressants)

RN 345995-21-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-ethanol, .alpha.-[(4-benzofuranyloxy)methyl]-3-(4-methoxybenzo[b]thien-2-yl)-, (.alpha.S,3-endo)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:416949 CAPLUS
DOCUMENT NUMBER: 135:33571
TITLE: Transition metal-cyclopentadienyl-tropane conjugates with affinity for monoamine transporters, their preparation and use as diagnostic or therapeutic agents
INVENTOR(S): Tamagnan, Gilles Denis; Baldwin, Ronald Martin; Innis, Robert B.
PATENT ASSIGNEE(S): Yale University, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040239	A2	20010607	WO 2000-US42447	20001201
WO 2001040239	A3	20001227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-168671P P 19991203
OTHER SOURCE(S): MARPAT 135:33571
GI



I



II



III

AB Transition metal-cyclopentadienyl-tropane conjugate compds., e.g., I, II [R1 = CO2R2, CH2OR2; R, R2 = H, (un)branched C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-12 aryl, C3-12 cycloalkyl, C3-12 heterocycloalkyl, C1-12 heteroarom. group wherein the heteroatom is N, O or S; Q = (un)substituted CpM(CO)3; M = Re, Tc, Mn or radioisotope; Cp = cyclopentadienyl] or III [Q = (un)substituted CpM(CO)3, same M, Cp; G = direct link, CO, R2NCO, CH:CH, C(O), SO2, O2C, CH2O(CH2)r'O(CH2)s; r = 1-4, s = 0-4, where r + s < 8; J = (CH2)n, n = 1-8; same R1; Ar = (un)substituted Ph group; when R1 = CO2Me or CH2OH, G .noteq. CO] useful as radiodiagnostic agents (no data) or as diagnostic or therapeutic agents for treatment of disorders related to monoamine transporter activity, such as clin. diagnosis of Parkinson's disease, are claimed, as are methods for their prepn. In an example, the binding affinity Ki of III [R1 = CO2Me, Ar = 4-ClC6H4, J = (CH2)3, G = O2C, Q = CpRe(CO)3; prepn. given] for dopamine transporter (DAT) was 4.18 .+-. 0.33 nM, for serotonin transporter (5-HTT) was 5.28 .+-. 0.21 nM and for norepinephrine transporter (NET) was 74.0 .+-. 8.2 nM.

IT **343612-67-9P**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation); PROC (Process)
(prepn. and binding affinity for dopamine, serotonin and norepinephrine transporters)

RN 343612-67-9 CAPLUS

CN Rhenium, tricarbonyl[(1,2,3,4,5-.eta.)-rel-1-[4-[(1R,2S,3S,5S)-3-(4-chlorophenyl)-2-(methoxycarbonyl)-8-azabicyclo[3.2.1]oct-8-yl]-1-oxobutoxy]-2,4-cyclopentadien-1-yl]- (9CI) (CA INDEX NAME)



L7 ANSWER 6 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:407940 CAPLUS
DOCUMENT NUMBER: 135:28327
TITLE: Dopamine and serotonin transporter ligands and imaging agents
INVENTOR(S): Kung, Hank; Meegalla, Sanath; Kung, Mei-ping; Plossl, Karl
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
SOURCE: U.S., 53 pp., Cont.-in-part of U.S. Ser. No. 545,327, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6241963	B1	20010605	US 1996-649782	19960517
CA 2233173	AA	19970424	CA 1996-2233173	19961021
WO 9714445	A1	19970424	WO 1996-US16908	19961021
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
AU 9711566	A1	19970507	AU 1997-11566	19961021
AU 716235	B2	20000224		
EP 929319	A1	19990721	EP 1996-942721	19961021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11514368	T2	19991207	JP 1996-516091	19961021
US 5980860	A	19991109	US 1998-116215	19980716

PRIORITY APPLN. INFO.:
US 1995-545327 B2 19951019
US 1996-649782 A 19960517
WO 1996-US16908 W 19961021

OTHER SOURCE(S): MARPAT 135:28327
GI



I

AB This invention presents a series novel tropane-based derivs. complexed with either Tc or Re that are specific for central nervous system receptors, in particular, dopamine or serotonin receptors. The compds. of the invention have utility, inter alia, as imaging agents for CNS receptors. Methods of using these novel compds. as imaging agents are presented, as are intermediates and methods for making these novel compds. For example, the 99Tc complex I was prepd. from HSCH2CH2NMeCH2CH2SH and the resp. tropane deriv. and its partition coeff., brain uptake and stratium/cerebellium ratios were detd.

IT **190021-90-0P**

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation); PROC (Process)

(metastable; prepn. and biodistribution studies as imaging agents)

RN 190021-90-0 CAPLUS

CN Technetium-99Tc, [methyl (1R,2S,3S,5S)-3-(4-fluorophenyl)-8-[2-(mercapto-.kappa.S)ethyl]-8-azabicyclo[3.2.1]octane-2-carboxylato][[2,2'-(methylimino-.kappa.N)bis[ethanethiolato-.kappa.S]](2-)]oxo-, (SP-5-34)-(9CI) (CA INDEX NAME)









REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:314260 CAPLUS
DOCUMENT NUMBER: 135:326940
TITLE: Convergent modeling strategies to account for SAR on 3-aminopyridazines binding to m1 muscarinic receptor
AUTHOR(S): Thevenin, Nicolas; Bernard, Philippe; Bourdon, Helene; Hibert, Marcel; Vermuth, Camille-Georges
CORPORATE SOURCE: Laboratoire de Pharmacochimie de la Communication Cellulaire, Faculte de Pharmacie, UMR CNRS/ULP 7081, Illkirch-Graffenstaden, F-67400, Fr.
SOURCE: Journal of Molecular Modeling [online computer file] (2000), 6(12), 637-647
CODEN: JMMOFK; ISSN: 0948-5023
URL: http://link.springer.de/link/service/journals/00894/papers/0006012/00060637.pdf
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English

AB The binding mode of 3-aminopyridazine analogs to the M1 muscarinic receptor has been studied by two complementary modeling strategies: the "active analog" approach and direct docking into a 3D model of the receptor. Modeling combined with SAR study: (i) accounts for the contribution to binding of both hydrophilic (Asp311, Asn617) and hydrophobic residues; (ii) illustrates the subtlety of ligand-receptor binding; (iii) highlights a binding site domain that might be responsible to partial or full agonism.

IT **146824-64-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); **BIOL (Biological study)**; USES (Uses)
(convergent modeling strategies to account for SAR on 3-aminopyridazines binding to m1 muscarinic receptor)

RN 146824-64-8 CAPLUS
CN Phenol, 2-[6-[[2-(8-azabicyclo[3.2.1]oct-8-yl)ethyl]amino]-4-methyl-3-pyridazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:208282 CAPLUS
DOCUMENT NUMBER: 134:237472
TITLE: Preparation of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists
INVENTOR(S): Fink, David M.; Freed, Brian S.; Hrib, Nicholas J.; Kosley, Raymond W., Jr.; Lee, George E.; Merriman, Gregory H.; Rauckman, Barbara S.
PATENT ASSIGNEE(S): Aventis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019833	A1	20010322	WO 2000-US24962	20000913

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-396081 A1 19990914
OTHER SOURCE(S): MARPAT 134:237472

AB RZOCH2CR1R2CH2NR3R4 [I; R = e.g., thieno[2,3-d]isoxazol-3-yl; R1 = OH or alkoxy; R2,R4 = H or alkyl; R3 = CH2R5, CH2CH(OH)R5, indanyl, etc.; R5 = cyclohex(en)yl, (hetero)aryl, etc.; Z = phenylene] were prepd. Thus, 3-bromothiophene was acylated by 3-(MeO)C6H4COCl and the oximated product cyclized to give, after O-demethylation, 3-RC6H4OH [R = thieno[2,3-d]isoxazol-3-yl] which was etherified by (R)-glycidyl tosylate and the product aminated by PhCHMeNH2 to give (R)-3-RC6H4OCH2CH(OH)CH2NMeCH2Ph (R as above). Data for biol. activity of I were given.

IT **330672-15-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of 1-amino-3-thienoisoxazolylphenoxy-2-propanols as dopamine D4 antagonists)

RN 330672-15-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-ethanol, 3-(1,2-benzisoxazol-3-yl)-.alpha.-[(3-thieno[2,3-d]isoxazol-3-ylphenoxy)methyl]-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:48253 CAPLUS
DOCUMENT NUMBER: 134:237378
TITLE: Synthesis and evaluation of novel 2-oxo-1,2-dihydro-3-quinolinecarboxamide derivatives as potent and selective serotonin 5-HT4 receptor agonists
AUTHOR(S): Suzuki, Masaji; Ohuchi, Yutaka; Asanuma, Hajime; Kaneko, Toshie; Yokomori, Sadakazu; Ito, Chika; Isobe, Yoshihiko; Muramatsu, Makoto
CORPORATE SOURCE: Research Center Taisho Pharmaceutical Co., Ltd., Saitama, 330-8530, Japan
SOURCE: Chemical & Pharmaceutical Bulletin (2001), 49(1), 29-39
CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of 8'-substituted N-(endo-8-azabicyclo[3.2.1]oct-3-yl)-1-isopropyl-2-oxo-1,2-dihydro-3-quinolinecarboxamides were synthesized. The 5-HT4 receptor agonistic activity was evaluated using the isolated guinea pig ileum prepn. Of the compds. synthesized, N-(endo-8-(3-hydroxypropyl)-8-azabicyclo[3.2.1]oct-3-yl)-1-isopropyl-2-oxo-1,2-dihydro-3-quinolinecarboxamide (TS-951) exhibited the most potent serotonin 5-HT4 receptor agonistic activity. This compd. had a high affinity for the serotonin 5-HT4 receptor although it had no affinities for other broad spectrum receptors. Furthermore, it remarkably enhanced gastrointestinal motility in conscious fed dogs without unfavorable effects that non-selective serotonin 5-HT4 receptor agonist has. TS-951 may be useful in improving gastrointestinal dysfunction.

IT **174486-49-8P**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation)
(synthesis and evaluation of novel 2-oxo-1,2-dihydro-3-quinolinecarboxamide derivs. as potent and selective serotonin 5-HT4 receptor agonists)

RN 174486-49-8 CAPLUS
CN 3-Quinolinecarboxamide, 1,2-dihydro-1-(1-methylethyl)-2-oxo-N-[(3-endo)-8-[2-(phenylsulfonyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:718232 CAPLUS
DOCUMENT NUMBER: 133:296449
TITLE: Preparation of benzhydrylpiperazines and related compounds as P-glycoprotein inhibitors for enhancing the antitumor activity of other cytotoxic agents.
INVENTOR(S): Arnold, Lee Daniel; Coe, Jotham Wadsworth; Kaneko, Takushi; Moyer, Mikel Paul
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 64 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6130217	A	20001010	US 1995-513880	19950920

OTHER SOURCE(S): MARPAT 133:296449
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB NR100R101R102 [R100 = Y1CH(Z1)(CH2)nY2B1A1Q1, CH2C(OH)R103CH2CH2OQ1, etc.; R103 = alkyl; Y1 = O, CH2, CH2CH2, bond; Z1 = H, OH, CF3, NO2, alkoxy; n = 1, 2; Y2 = O, S, NH, NMe, CONH, bond; B1 = bond, (substituted) Ph; A1 = bond, alkylene, O, S, NH; Q1 = specified (substituted) azolyl, (fused) Ph, etc.; R101 = R100, H, alkyl, (substituted) alkenylphenyl, alkylphenyl; R102 = Q4, Q5, Q6, etc.; X9 = H, OH, Cl, F, alkoxy, CF3, alkyl; dotted line = optional double bond; n = 1, 2; Q = S, O; R101R102N = Q7, Q8, etc.; with provisos], were prepd. as P-glycoprotein inhibitors (no data). Thus, 1-benzhydrylpiperazine and 2-[2-(oxiran-2-ylmethoxy)phenyl]benzothiazole were refluxed 16 h in EtOH to give 42% 1-(4-benzhydrylpiperazin-1-yl)-3-(2-benzothiazol-2-ylphenoxy)propan-2-ol.

IT **300705-89-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of benzhydrylpiperazines and related compds. as P-glycoprotein inhibitors for enhancing the antitumor activity of other cytotoxic agents)

RN 300705-89-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octan-3-one, 8-[2-hydroxy-3-(5-quinolinyloxy)propyl]-

2,4-bis(phenylmethyl)-, (1R,2S,4R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:690793 CAPLUS
DOCUMENT NUMBER: 134:13278
TITLE: The search for selective blockers of the NMDA and AMPA/kainate receptors in a series of bis-ammonium compounds with adamantyl radicals
AUTHOR(S): Gmiro, V. E.; Serdyuk, S. E.
CORPORATE SOURCE: Anichkov Dep. of Neuropharmacology, Inst. of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, 197022, Russia
SOURCE: Eksperimental'naya i Klinicheskaya Farmakologiya (2000), 63(1), 7-13
CODEN: EKFAE9; ISSN: 0869-2092
PUBLISHER: Izdatel'stvo Folium
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB Two groups of substances capable of selectively blocking the NMDA and AMPA/kainate receptors in expts. on intact animals were found in a series of bis-ammonium compds. with adamantyl radicals. The selective NMDA receptor blockers (IEM-1754, IEM-1755, IEM-1752), as well as the ref. agents MK-801 and memantine, produced anticonvulsant, antiischemic, and antihypoxant effects and prevented the loss of exptl. animals from toxic doses of NMDA. The selective AMPA/kainate receptor blockers (IEM-1553, IEM-1751, IEM-1592, and DNQX) also produced the anticonvulsant, antiischemic, and antihypoxant effects, but did not prevent from the loss of animals caused by the toxic doses of NMDA. The max. activity was obsd. for IEM-1754, the activity of which exceeded that of MK-801 (by a factor of 5-10) and memantine (by a factor of 300-800) in all the test objects.

IT **309955-10-0**, IEM 1752
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); **BIOL (Biological study)**; USES (Uses)
(search for selective blockers of NMDA and AMPA/kainate receptors in a series of bis-ammonium compds. with adamantyl radicals)

RN 309955-10-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-hydroxy-8-methyl-8-[5-(tricyclo[3.3.1.13,7]dec-1-ylamino)pentyl]-, bromide, hydrobromide (9CI) (CA INDEX NAME)





● Br^-

● HBr

L7 ANSWER 12 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:810820 CAPLUS
DOCUMENT NUMBER: 132:146151
TITLE: N-phenylalkyl-substituted tropane analogs of boat conformation with high selectivity for the dopamine versus serotonin transporter
AUTHOR(S): Prakash, K. R. C.; Tamiz, Amir P.; Araldi, Gian Luca; Zhang, Mei; Johnson, Kenneth M.; Kozikowski, Alan P.
CORPORATE SOURCE: Drug Discovery Program, Institute for Cognitive and Computational Sciences, Georgetown University Medical Center, Washington, DC, 20007-2197, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(23), 3325-3328
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of N-phenylalkyl-substituted tropane analogs of boat conformation was synthesized, and these tropanes were evaluated for their ability to inhibit high affinity uptake of dopamine (DA) and serotonin (5-HT) into striatal nerve endings (synaptosomes). Some of these compds. exhibit high affinity for the DA transporter with a 5-HT/DA transporter selectivity ratio of > 50.

IT **257926-27-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation)
(N-phenylalkyl-substituted tropane analogs of boat conformation with high selectivity for dopamine vs. serotonin transporter)

RN 257926-27-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-[2-(4-fluorophenoxy)ethyl]-2,3-bis(4-fluorophenyl)-, (1R,2R,3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:747671 CAPLUS
DOCUMENT NUMBER: 132:30340
TITLE: Cage dimeric N-acyl- and N-acyloxy-4-aryl-1,4-dihydropyridines as first representatives of a novel class of HIV-1 protease inhibitors
AUTHOR(S): Hilgeroth, Andreas; Billich, Andreas
CORPORATE SOURCE: Institut Pharmazeutische Chemie, Martin-Luther-Univ., Halle/Saale, D-06120, Germany
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1999), 332(11), 380-384
CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of a series of novel cage dimeric N-acyl and N-acyloxy-4-aryl-1,4-dihydropyridines starting either from solid-state synthetic ester dimers or form monomeric 4-aryl-1,4-dihydropyridines is presented. Their biol. evaluation as novel HIV-1 protease inhibitors showed 2 compds. with inhibitory activities of 52 (50 .mu.M) and 49% (25.mu.M), resp. Within each series of N-acyl and N-acyloxy derivs. NCOBz and NBoc groups were found to be the best substituents. Although they exhibiting only moderate activities these cage dimers hold promise as a class of novel non-peptidic HIV-1 protease inhibitors.

IT **252668-62-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(cage dimeric N-acyl- and N-acyloxy-4-aryl-1,4-dihydropyridines, a novel class of HIV-1 protease inhibitors)

RN 252668-62-5 CAPLUS
CN 3,9-Diazapentacyclo[6.4.0.02,7.04,11.05,10]dodecane-3,9-dicarboxylic acid, 1,5,7,11-tetrakis(hydroxymethyl)-6,12-diphenyl-, diphenyl ester, stereoisomer (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:565911 CAPLUS
DOCUMENT NUMBER: 131:179801
TITLE: P-glycoprotein and MRP inhibitors for chemosensitizing multidrug resistant tumor cells
INVENTOR(S): Smith, Charles
PATENT ASSIGNEE(S): Fox Chase Cancer Center, USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943323	A1	19990902	WO 1999-US4439	19990226
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6248752	B1	20010619	US 1999-257829	19990225

PRIORITY APPLN. INFO.: US 1998-76212P P 19980227
OTHER SOURCE(S): MARPAT 131:179801

AB Various compds., such as dihydropyridines, thiaxanthenes, phenothiazines, cyclosporines and acridonecarboxamides, effective in sensitizing drug resistant tumor cells are disclosed which are useful in cancer therapy. The compds. of the invention are ether: (1) selective inhibitors of P-glycoprotein function, (2) selective inhibitors of MRP function, or (3) dual inhibitors of both transporters. The compds. increased the toxicity of antitumor drug, e.g. actinomycin D toward P-glycoprotein-mediated multidrug resistant cells MCF-7/ADR and/or vincristine toward MRP-mediated multidrug resistant cells HL-60/ADR. Most of the compds. tested have low intrinsic cytotoxicity (<20% of cells killed by doses of 10 .mu.g/mL).

IT **240486-48-0**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); **BIOL (Biological study)**; USES (Uses)
(P-glycoprotein and MRP inhibitors for chemosensitizing multidrug resistant tumor cells)

RN 240486-48-0 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, 3-[(hydrazinocarbonyl)oxy]-, 4-chlorophenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:394857 CAPLUS
DOCUMENT NUMBER: 131:110837
TITLE: Cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for the development of a novel class of HIV-1 protease inhibitors
AUTHOR(S): Hilgeroth, Andreas; Billich, Andreas
CORPORATE SOURCE: Inst. Pharmazeutische Chemie, Martin-Luther-Univ., Halle/Saale, D-06120, Germany
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1999), 332(1), 3-5
CODEN: ARPMAS; ISSN: 0365-6233
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal
LANGUAGE: English

AB N-acyl and acyloxy derivs. of the title compds. were prepd. and tested as HIV-1 protease inhibitors. They reached IC50 and better values at 25 and 50 .mu.M, resp. With the exception of R2 = CH3, compds. with R1 = H are better inhibitors than those with R1 = OCH3. Inhibition increased within each series of N-acyl and acyloxy derivs., resp., from Me to Bzl, OPh, and Boc.

IT **233272-00-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(cage dimeric 4-aryl-1,4-dihydropyridines as promising lead structures for development of HIV-1 protease inhibitors)

RN 233272-00-9 CAPLUS
CN 3,9-Diazapentacyclo[6.4.0.02,7.04,11.05,10]dodecane-3,9-dicarboxylic acid, 1,5,7,11-tetrakis(hydroxymethyl)-6,12-diphenyl-, diphenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:246879 CAPLUS

DOCUMENT NUMBER: 130:296684
TITLE: Preparation of indazole- and 2-oxobenzamidazole-3-carboxamides as 5-HT4 agonists and antagonists
INVENTOR(S): Cohen, Marlene Lois; Schaus, John Mehnert; Thompson, Dennis Charles
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 908459	A1	19990414	EP 1998-308069	19981005
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
US 6069152	A	20000530	US 1997-946495	19971007
CA 2304826	AA	19990415	CA 1998-2304826	19980924
WO 9917772	A1	19990415	WO 1998-US19992	19980924
W: AL, AM, AT, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001518504	T2	20011016	JP 2000-514643	19980924
US 6117882	A	20000912	US 1999-338707	19990623

PRIORITY APPLN. INFO.: US 1997-946495 A 19971007
WO 1998-US19992 W 19980924
OTHER SOURCE(S): MARPAT 130:296684
GI



I



II

AB The title compds. [I; AD = C:N,NC:O; n = 1-5; R = H, halo, alkyl, etc.; R1 = H, alkyl, (un)substituted cycloalkyl; R2, R3 = H; R2R3 taken together form a bridge of 1-4 methylene units; X = OR4, NR4R5; R4 = H, alkyl, (un)substituted cycloalkyl, etc.; R5 = H; NR4R5 = pyrrolidino, piperazino, piperidino, etc.], antagonists and partial agonists for the serotonin receptor 5-HT4 which are useful for treatment of disorders caused by or affected by dysfunction of the 5-HT4 receptor such as anxiety, pain, depression, schizophrenia, memory disorders, dementia, irritable bowel syndrome, nausea, gastroesophageal reflux disease, dyspepsia, gastrointestinal motility disorders, constipation, atrial fibrillation, arrhythmias, tachycardia, urinary retention, urinary incontinence, or pain on urination, were prepd. and formulated. E.g., methanesulfonylation of N-[1-(2-aminoethyl)piperidin-4-yl]-1-isopropylindazole-3-carboxamide (prepn. given) afforded 60% II. Compds. I reduced the obsd. relaxations of esophagus smooth muscle (of rats) at .ltoreq. 10 .mu.M.

IT **223261-67-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of indazole- and 2-oxobenzamidazole-3-carboxamides as 5-HT4 agonists and antagonists)

RN 223261-67-4 CAPLUS

CN 1H-Benzimidazole-1-carboxamide, N-[8-[3-(4-fluorophenoxy)propyl]-8-azabicyclo[3.2.1]oct-3-yl]-2,3-dihydro-2-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1998:541731 CAPLUS

DOCUMENT NUMBER: 129:254351

TITLE: Synthesis and in vitro binding of N-alkyl-2,3-dimethoxy[3.3.1]azabicyclononane benzamides at dopamine D2 and D3 receptors

AUTHOR(S): Yang, Biao; Johnston, Douglas E., Jr.; Luedtke, Robert R.; Hammond, Philip S.; Mach, Robert H.

CORPORATE SOURCE: Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, USA

SOURCE: Med. Chem. Res. (1998), 8(3), 115-131
CODEN: MCREEB; ISSN: 1054-2523

PUBLISHER: Birkhaeuser Boston

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of N-alkyl analogs of 2,3-dimethoxy-N-(9-benzyl)-9-azabicyclo[3.3.1]nonan-3.beta.-yl-benzamide was prepd. and their affinity

for dopamine D2 and D3 receptors was measured in vitro to explore the spatial requirements and relative degree of bulk tolerance in the N-benzyl region of the lead compd. These results suggest a higher degree of bulk tolerance in this binding region of the D2 receptor than in the D3 receptor subtype. These results provide information for the development of pharmacophoric models of the D2 and D3 dopamine receptor subtypes that can be used for the future development of selective antagonists at these two structurally and pharmacol. similar receptor subtypes.

IT **213532-07-1P**
RL: BPR (Biological process); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation); PROC (Process)
(prepn. and structure activity relations of in vitro binding of alkyl dimethoxyazabicyclononanebenzamides at dopamine D2 and D3 receptors)

RN 213532-07-1 CAPLUS
CN Benzamide, 2,3-dimethoxy-N-[(3-exo)-9-(3-phenoxypropyl)-9-azabicyclo[3.3.1]non-3-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 18 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:372639 CAPLUS
DOCUMENT NUMBER: 129:40130
TITLE: Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
INVENTOR(S): Swain, Philip A.; Schad, Victoria C.; Greenstein, Julia L.; Exley, Mark A.; Fox, Barbara S.; Powers, Stephen P.; Gefter, Malcolm L.; Briner, Thomas J.
PATENT ASSIGNEE(S): ImmuLogic, Inc., USA
SOURCE: U.S., 44 pp. Cont.-in-part of U.S. 414,971, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5760184	A	19980602	US 1995-563673	19951128
US 5773003	A	19980630	US 1995-456444	19950601
US 5840307	A	19981124	US 1995-457206	19950601
CA 2216658	AA	19961003	CA 1996-2216658	19960327
WO 9630049	A2	19961003	WO 1996-US4189	19960327
WO 9630049	A3	19970306		

W: AM, AT, AU, BB, BG, BR, BY, CA, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9653749	A1	19961016	AU 1996-53749	19960327
EP 814843	A2	19980107	EP 1996-910595	19960327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 5876727	A	19990302	US 1996-720487	19960930
US 6054127	A	20000425	US 1997-884497	19970627
US 2002032316	A1	20020314	US 2001-882803	20010614

PRIORITY APPLN. INFO.:

US 1995-414971	B2	19950330
US 1995-563673	A	19951128
WO 1996-US4189	W	19960327
US 1996-720487	A1	19960930
US 1999-257821	B1	19990225

OTHER SOURCE(S): MARPAT 129:40130

AB Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo are disclosed. Methods of prepg. the hapten-carrier conjugates and therapeutic compns. are also disclosed. Where the hapten is a drug of abuse, a therapeutic compn. contg. the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic compn. is suitable for co-therapy with other conventional drugs.

IT **183793-36-4P**
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(hapten-carrier conjugates for use in cocaine or drug-abuse therapy and methods for prepn.)

RN 183793-36-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-butanoic acid, 3-(benzoyloxy)-2-(methoxycarbonyl)-.gamma.-oxo-, 2-nitro-4-sulfophenyl ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 19 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1998:270001 CAPLUS
DOCUMENT NUMBER:	128:316920
TITLE:	Synthesis and Structure-Activity Relationships of Potent and Orally Active 5-HT4 Receptor Antagonists: Indazole and Benzimidazolone Derivatives
AUTHOR(S):	Schaus, John M.; Thompson, Dennis C.; Bloomquist, William E.; Susemichel, Alice D.; Calligaro, David O.; Cohen, Marlene L.
CORPORATE SOURCE:	Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA

SOURCE: J. Med. Chem. (1998), 41(11), 1943-1955
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Indole-3-carboxamides, indazole-3-carboxamides, and benzimidazolone-3-carboxamides were synthesized and evaluated for antagonist affinity at the 5-HT4 receptor in the rat esophagus. The endo-3-tropanamine derivs. in the indazole and benzimidazolone series possessed greater 5-HT4 receptor affinity than the corresponding indole analogs. 5-HT4 receptor antagonist affinity was further increased by alkylation at N-1 of the arom. heterocycle. In 1-isopropylindazole-3-carboxamides, replacement of the bicyclic tropane ring system with the monocyclic piperidine ring system or an acyclic aminoalkylene chain led to potent 5-HT4 receptor antagonists. In particular, those systems in which the basic amine was substituted with groups capable of forming H bonds showed increased 5-HT4 receptor antagonist activity. While some of these compds. displayed high affinity for other neurotransmitter receptors (in particular, 5-HT3, .alpha.1, and 5-HT2A receptors), as the conformational flexibility of the amine moiety increased, the selectivity for the 5-HT4 receptor also increased. From this series of compds., the authors identified LY353433 (1-(1-methylethyl)-N-[2-[4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]-1-piperidinyl]ethyl]-1H-indazole-3-carboxamide) as a potent and selective 5-HT4 receptor antagonist with clin. suitable pharmacodynamics.

IT **207296-60-4P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(synthesis and structure-activity relationships of potent and orally active indazole and benzimidazolone 5-HT4 receptor antagonists)

RN 207296-60-4 CAPLUS

CN 1H-Indazole-3-carboxamide, N-[(3-endo)-8-[3-(4-fluorophenoxy)propyl]-8-azabicyclo[3.2.1]oct-3-yl]-1-(1-methylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

L7 ANSWER 20 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:691221 CAPLUS
DOCUMENT NUMBER: 128:20103

TITLE: Phototoxicity of some novel porphyrin hybrids against the human leukemic cell line TF-1

09/ 995,177

AUTHOR(S): Viola, A.; Mannoni, P.; Chanon, M.; Julliard, M.; Mehta, G.; Maiya, B. G.; Muthusamy, S.; Sambaiah, T.
CORPORATE SOURCE: Laboratoire AM3 - ESA-CNRS 6009, Faculte des Sciences Saint-Jerome, 13397, Marseille, 20, Fr.
SOURCE: J. Photochem. Photobiol., B (1997), 40(3), 263-272
CODEN: JPPBEG; ISSN: 1011-1344
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Photodynamic induced cytotoxicity by porphyrin-DNA cross linker/intercalator hybrid diads and triads has been studied on the human leukemic cell line TF-1. Cells were incubated for 1 to 4 h with these new photosensitizers and irradiated with white light. Cell survival was assessed by the propidium iodide staining, using flow cytometry anal. A comparison of the dark and light cell survival factor values suggests that irradn. has a significant effect on the toxicity at low concns. for the porphyrin-chlorambucil diad and to a lesser extent at high concns. for the porphyrin-acridone diad, the porphyrin-acridine diad and the porphyrin-cholic acid-chlorambucil triad. While the intrinsic antileukemic (via DNA crosslinking) activity of the chlorambucil moiety and the structural details may be responsible for the photoenhancement of the toxicity, the presence of acridine or acridone which are avid intercalators of DNA, is responsible for a similar effect seen for diads.
IT **155245-04-8**
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); **BIOL (Biological study)**; USES (Uses)
(phototoxicity of porphyrin hybrids against the human leukemic cell line TF-1)
RN 155245-04-8 CAPLUS
CN 9(10H)-Acridinone, 10-[3-[4-[10,15,20-tris(4-methylphenyl)-21H,23H-porphin-5-yl]phenoxy]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



O

L7 ANSWER 21 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:380992 CAPLUS
DOCUMENT NUMBER: 126:340548
TITLE: Dopamine and serotonin transporter ligand tropane-based derivatives, their technetium and rhenium complexes, and preparation thereof, for use as imaging agents for CNS receptors
INVENTOR(S): Kung, Hank F.; Meegalla, Sanath; Kung, Mei-ping; Ploessl, Karl
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA; Kung, Hank F.; Meegalla, Sanath; Kung, Mei-Ping; Ploessl, Karl
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9714445	A1	19970424	WO 1996-US16908	19961021
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG				
US 6241963	B1	20010605	US 1996-649782	19960517
AU 9711566	A1	19970507	AU 1997-11566	19961021
AU 716235	B2	20000224		
EP 929319	A1	19990721	EP 1996-942721	19961021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 11514368	T2	19991207	JP 1996-516091	19961021

PRIORITY APPLN. INFO.: US 1995-545327 A 19951019
US 1996-649782 A 19960517
WO 1996-US16908 W 19961021
OTHER SOURCE(S): MARPAT 126:340548

AB Tropane-based derivs. complexed with either technetium or rhenium that are specific for central nervous system receptors, in particular, dopamine or serotonin receptors, are disclosed. The compds. of the invention have utility, inter alia, as imaging agents for CNS receptors. Methods of using these novel compds. as imaging agents are presented, as are intermediates and methods for making these compds.

IT **190022-01-6**
RL: BPR (Biological process); PRP (Properties); THU (Therapeutic use); **BIOL (Biological study)**; PROC (Process); USES (Uses)
(dopamine and serotonin transporter ligand tropane-based derivs., technetium and rhenium complexes, prepn., and use as imaging agents for CNS receptors)

RN 190022-01-6 CAPLUS
CN Rhenium, [methyl 3-(4-chlorophenyl)-8-[2-(mercapto-.kappa.S)ethyl]-8-azabicyclo[3.2.1]octane-2-carboxylato][[2,2'-(methylimino-.kappa.N)bis[ethanethiolato-.kappa.S]](2-)]oxo-, [SP-5-34-[1R-(exo,exo)]]-

(9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





L7 ANSWER 22 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:303430 CAPLUS
DOCUMENT NUMBER: 126:277394
TITLE: Preparation of acridone compounds as drugs
INVENTOR(S): Miyamoto, Mitsuaki; Yoshiuchi, Tatsuya; Sato, Keizo; Kaino, Makoto; Takashima, Yoshihiro; Moriya, Katsuhiro; Sakuma, Yoshinori; Yamada, Koji; Harada, Kokichi; Nishizawa, Yukio; Kobayashi, Seiichi; Okita, Makoto; Katayama, Koichi; et al.
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan; Miyamoto, Mitsuaki; Yoshiuchi, Tatsuya; Sato, Keizo; Kaino, Makoto
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

09/ 995,177

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9712872	A1	19970410	WO 1996-JP2880	19961003
W: AU, CA, CN, HU, KR, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2232990	AA	19970410	CA 1995-2232990	19951002
JP 09249650	A2	19970922	JP 1996-261669	19961002
CA 2233643	AA	19970410	CA 1996-2233643	19961003
AU 9671453	A1	19970428	AU 1996-71453	19961003
EP 857721	A1	19980812	EP 1996-932811	19961003
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.:

JP 1995-257944	19951004
JP 1995-301570	19951120
JP 1995-317867	19951206
JP 1995-317868	19951206
JP 1996-1339	19960109
JP 1996-1340	19960109
WO 1996-JP2880	19961003

OTHER SOURCE(S): MARPAT 126:277394

GI



I



II

AB The title compds. [I; R1-R6 = H, OH, halo, lower alkyl or alkoxy, cycloalkyl, etc.; Y = (CH2)p(B)m(CH2)nZ; m = 0-1; p, n = 0-6; B = lower alkylene, optionally substituted arylene, etc.; Z = cyano, optionally protected carboxy, acyl, NR7R8; R7, R8 = H, lower alkyl or alkoxy, hydroxyalkyl, etc.; D = O, S] and pharmacol. acceptable salts thereof are prepd. I are useful in the prevention and treatment of diseases in which chem. transmitters (histamine, leukotriene, etc.) participate, typified by asthma, allergic rhinitis, atopic dermatitis, urticaria, hay fever, digestive tract allergy, food allergy, etc. Thus, acridone deriv. (II; X = NH2) was refluxed with C6H4CHO in EtOH and then treated with NaBH4 to give the title compd. II (X = C6H4CH2NH), which showed IC50 of 3 .mu.M against serotonin releasing when tested on rat RBL-2H3 cells.

IT **189009-17-4P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study);**

PREP (Preparation); USES (Uses)
(prepn. of acridone compds. as drugs)
RN 189009-17-4 CAPLUS
CN 9(10H)-Acridinone, 3,4-dimethyl-10-[3-[[3-(1H-tetrazol-5-yl)phenyl]amino]propyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 23 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:231044 CAPLUS
DOCUMENT NUMBER: 126:251055
TITLE: Microbiological Oxygenation of Bridgehead Azabicycloalkanes
AUTHOR(S): Davis, Charles R.; Johnson, Roy A.; Cialdella, Joyce I.; Liggett, Walter F.; Mizsak, Stephen A.; Marshall, Vincent P.
CORPORATE SOURCE: Research Laboratories, Pharmacia Upjohn Inc., Kalamazoo, MI, 49001, USA
SOURCE: J. Org. Chem. (1997), 62(7), 2244-2251
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of N-substituted bridgehead azabicycloalkanes has been prepd. and examd. as substrates for microbiol. oxygenation using the fungi Beauveria bassiana, Rhizopus nigricans, Aspergillus ochraceus, and Rhizopus arrhizus. Oxygenation using B. bassiana of N-tosyl-7-azabicyclo[2.2.1]heptane gave N-[p-(hydroxymethyl)benzenesulfonyl]-7-azabicyclo[2.2.1]heptane (56% yield), of N-(phenyloxycarbonyl)-7-azabicyclo[2.2.1]heptane gave the 2-endo-ol (56% yield, 51% ee), of N-BOC-7-azabicyclo[2.2.1]heptane gave the 2-endo-ol (10% yield), of N-Cbz-7-azabicyclo[2.2.1]heptane gave the 2-endo-ol (28%), of N-(phenyloxycarbonyl)-8-azabicyclo[3.2.1]octane gave the 3-endo-ol, and of N-(phenyloxycarbonyl)-9-azabicyclo[3.3.1]nonane gave the 3-exo-ol (30%) and 3-one (16%). Oxygenation using R. nigricans of N-BOC-7-azabicyclo[2.2.1]heptane gave the 2-endo-ol (63% yield, 28% ee) and the 2-exo-ol (28% yield, 42% ee). Oxidn. of the N-BOC-7-azabicyclo[2.2.1]heptan-2-ols gave the 2-ketone, a synthetic intermediate useful for conversion to the natural product, epibatidine. Oxygenation of N-(phenyloxycarbonyl)-7-azabicyclo[2.2.1]heptane using R. arrhizus gave the 2-endo-ol (5% yield, 31% ee) and the 2-exo-ol (18% yield, 22% ee). Oxygenation of N-(phenyloxycarbonyl)-8-azabicyclo[3.2.1]octane using A. ochraceus gave the 3-endo-ol (36%) and the 3-one (4%).
IT **68043-76-5P**
RL: BPR (Biological process); RCT (Reactant); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation); PROC (Process)
(microbiol. oxygenation of bridgehead azabicycloalkanes)

RN 68043-76-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-carboxylic acid, phenyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 24 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:731803 CAPLUS

DOCUMENT NUMBER: 126:1214

TITLE: Hapten-carrier conjugates, and their preparation, for use in drug-abuse therapy

INVENTOR(S): Swain, Philip A.; Schad, Victoria C.; Greenstein, Julia L.; Exley, Mark A.; Fox, Barbara S.; Powers, Stephen P.; Gefter, Malcolm L.; Briner, Thomas J.

PATENT ASSIGNEE(S): Immulogic Pharmaceutical Corporation, USA

SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9630049	A2	19961003	WO 1996-US4189	19960327
WO 9630049	A3	19970306		
W: AM, AT, AU, BB, BG, BR, BY, CA, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5760184	A	19980602	US 1995-563673	19951128
AU 9653749	A1	19961016	AU 1996-53749	19960327
EP 814843	A2	19980107	EP 1996-910595	19960327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.:
US 1995-414971 A 19950330
US 1995-563673 A 19951128
WO 1996-US4189 W 19960327

OTHER SOURCE(S): CASREACT 126:1214; MARPAT 126:1214

AB Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic compn., are disclosed. Methods of prepg. said conjugates and therapeutic compns. are also disclosed. Where the hapten is a drug of abuse, a therapeutic compn. contg. the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic compn. is suitable for co-therapy with other conventional drugs. Data are presented which demonstrate that cocaine-carrier conjugates can be synthesized which induce high-titer, cocaine-specific antibody responses.

IT **183793-36-4D**, conjugates with cholera toxin B

RL: THU (Therapeutic use); **BIOL (Biological study)**; USES (Uses)
(hapten-carrier conjugate prepn. for drug-abuse therapy)

RN 183793-36-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-butanoic acid, 3-(benzoyloxy)-2-(methoxycarbonyl)-.gamma.-oxo-, 2-nitro-4-sulfophenyl ester, (1R,2R,3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 25 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:466897 CAPLUS

DOCUMENT NUMBER: 125:142545

TITLE: Preparation of heterocyclic LTA4 hydrolase inhibitors

INVENTOR(S): Chandrakumar, Nizal Samuel; Chen, Barbara Baosheng; Clare, Michael; Desai, Bipinchandra Nanubhai; Djuric, Steven Wakefield; Docter, Stephan Hermann; Gasiecki, Alan Frank; Haack, Richard Arthur; Liang, Chi-Dean; et al.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: PCT Int. Appl., 342 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9611192	A1	19960418	WO 1995-US12365	19951010
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5585492	A	19961217	US 1994-321183	19941011
CA 2202371	AA	19960418	CA 1995-2202371	19951010
AU 9536865	A1	19960502	AU 1995-36865	19951010
EP 804427	A1	19971105	EP 1995-934554	19951010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
JP 10512848	T2	19981208	JP 1995-512608	19951010

PRIORITY APPLN. INFO.: US 1994-321183 19941011
WO 1995-US12365 19951010

OTHER SOURCE(S): MARPAT 125:142545

GI



I

AB The title compds. Ar1QAr2YRZ [Ar1, Ar2 = (un)substituted aryl; Z = (un)substituted nitrogen-contg. moiety which may be an acyclic, cyclic or bicyclic amine or (an) (un)substituted monocyclic or bicyclic nitrogen-contg. heteroarom. moiety; Q, Y = linking group; R = alkylene], useful in the treatment of inflammatory diseases which are mediated by LTB4 prodn. [e.g., psoriasis (no data), ulcerative colitis (no data), irritable bowel syndrome (no data), and asthma (no data)], are prepd. Thus, 4-phenoxyphenol was condensed with 1-(2-chloroethyl)pyrrolidine hydrochloride, producing pyrrolidine I, which demonstrated a IC50 of 30 nM in a recombinant human LTA4 hydrolase assay.

IT **179020-61-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of heterocyclic LTA4 hydrolase inhibitors)

RN 179020-61-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-[2-[4-(phenylmethyl)phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 26 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:452004 CAPLUS
DOCUMENT NUMBER: 125:142725
TITLE: LTA4-Hydrolase inhibitors, pharmaceutical compositions, and methods of use
INVENTOR(S): Chandrakumar, Nizal Samuel; Chen, Barbara Baosheng; Clare, Michael; Desai, Bipinchandra Nanubhai; Djuric, Steven Wakefield; Docter, Stephan Hermann; Gasiecki, Alan Frank; Haack, Richard Arthur; Liang, Chi-Dean; et al.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 362 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9610999	A2	19960418	WO 1995-US12367	19951010
WO 9610999	A3	19960919		

W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES,

FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, TJ
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,
LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
SN, TD, TG

US 5723492	A	19980303	US 1995-469606	19950606	
CA 2202368	AA	19960418	CA 1995-2202368	19951010	
AU 9536866	A1	19960502	AU 1995-36866	19951010	
EP 786992	A2	19970806	EP 1995-934555	19951010	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
JP 10512542	T2	19981202	JP 1995-512609	19951010	

PRIORITY APPLN. INFO.: US 1994-321184 19941011
WO 1995-US12367 19951010

OTHER SOURCE(S): MARPAT 125:142725

GI



II



@ HCl III

AB The invention provides compds. Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof [wherein Ar1 and Ar2 = (un)substituted (hetero)aryl moieties; Z = (un)substituted N-contg. moiety which may be an acyclic, cyclic, or bicyclic amine, or an (un)substituted monocyclic or bicyclic, N-contg., heteroarom. moiety; Q = O, CH2, OCH2, CH2O, NH, NHCH2, CH2NH, CF2, CH:CH, CH2CH2, or bond; R = alkylene moiety; Y = O, S, NH, S(O), S(O)2; Z is bound to R through a N atom]. I and their pharmaceutical compns. are useful in the treatment of inflammatory diseases which are mediated by LTB4 prodn., such as psoriasis, ulcerative colitis, inflammatory bowel disease, and asthma. Over 500 examples cover syntheses of various I and precursors, plus results of 3 bioassays. For instance, etherification of 1-(2-hydroxyethyl)pyrrolidine with 2-bromothiazole and NaH gave 74% 2-(2-pyrrolidinoethoxy)thiazole, which was lithiated with BuLi and treated with PhCHO to give the 5-(.alpha.-hydroxybenzyl) deriv. in 66% yield. This was reduced with Et3SiH and CF3CO2H to give 74% title compd. II. In a recombinant human LTA4 hydrolase assay, title compd. III had IC50 of 2 nM.

IT **179020-61-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of (hetero)aryloxyalkylamines and analogs as LTA4 hydrolase inhibitors)

RN 179020-61-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-carboxylic acid, 8-[2-[4-(phenylmethyl)phenoxy]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 27 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:393877 CAPLUS
DOCUMENT NUMBER: 125:52471
TITLE: Tc-99m-Labeled Tropanes as Dopamine Transporter Imaging Agents
AUTHOR(S): Meegalla, Sanath; Ploessl, Karl; Kung, Mei-Ping; Chumpradit, Sumalee; Stevenson, D. Andrew; Frederick, Dana; Kung, Hank F.
CORPORATE SOURCE: Departments of Radiology and Pharmacology, University of Pennsylvania, Philadelphia, PA, 19104, USA
SOURCE: Bioconjugate Chem. (1996), 7(4), 421-429
CODEN: BCCHES; ISSN: 1043-1802
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The development of novel Tc-99m-labeled tropane derivs. as dopamine transporter imaging agents is reported. A series of neutral and lipophilic conjugated complexes, contg. N-(alkylthiolato)tropane, aminobis(ethylthiolato), and a [99mTc]TcO3+ center core, was prepd. and evaluated as central nervous system (CNS) dopamine transporter imaging agents in rats. One of the compds., [99mTc]technetium, [methyl 3-(4-chlorophenyl)-8-(2-mercaptoethyl)-8-azabicyclo[3.2.1]octane-2-carboxylato-S][[2,2'-(methylimino)bis[ethanethiolato]](2-)-N,S,S']oxo (25), displayed low initial uptake in rat brain (0.1% at 2 min post i.v. injection); the striatal/cerebellar (ST/CB) ratio reached 3.50 at 60 min after an i.v. injection. The specific uptake can be blocked by pretreating rats with a competing dopamine transporter binding agent, .beta.-CIT (RTI-55, N-methyl-2.beta.-carbomethoxy-3.beta.-(4-iodophenyl)tropane; i.v., 1 mg/kg), which reduced the regional brain uptake ratio (ST/CB) to 1.0. In contrast, the specific uptake in striatum was not affected by pretreating rats with a noncompeting ligand, haldol (i.v., 1 mg/kg). In vitro autoradiog. of rat brain sections exhibited elevated labeling in striatum, major islands of Calleja, and olfactory tubercle regions, where dopamine neurons are known to be concd. This series of compds. is the first example of technetium-99m labeled CNS receptor-specific imaging agents and may provide a convenient source of short-lived imaging agents for routine diagnosis of CNS abnormality in conjunction with single photon emission computed tomog.

IT **171296-10-9P**
RL: BPR (Biological process); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); PROC (Process); USES (Uses)
(metastable; 99mTc-labeled tropanes as brain dopamine transporter SPECT agents)

RN 171296-10-9 CAPLUS
CN Technetium-99Tc, [methyl 3-(4-chlorophenyl)-8-(2-mercaptoethyl)-8-azabicyclo[3.2.1]octane-2-carboxylato-S][[2,2'-(methylimino)bis[ethanethiolato]](2-)-N,S,S']oxo-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





L7 ANSWER 28 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:222231 CAPLUS
DOCUMENT NUMBER: 124:260855
TITLE: Preparation of acridone derivatives as allergy inhibitors
INVENTOR(S): Myamoto, Mitsuaki; Yoshiuchi, Tatsuya; Abe, Shinya; Tanaka, Masayuki; Morya, Katsuhiro; Katayama, Satoshi; Yamanaka, Teiji; Yamada, Koji
PATENT ASSIGNEE(S): Eisai Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07316135	A2	19951205	JP 1995-75208	19950331
WO 9712871	A1	19970410	WO 1995-JP2007	19951002

W: AU, CA, CN, FI, KR, NO, RU, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
AU 9535786 A1 19970428 AU 1995-35786 19951002
EP 877020 A1 19981111 EP 1995-932954 19951002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE
PRIORITY APPLN. INFO.: JP 1994-85313 19940401
WO 1995-JP2007 19951002
OTHER SOURCE(S): MARPAT 124:260855
GI



I



II

AB The title compds. I [R1 - R6 = H, alkyl, halo, etc.; R7, R8 = H, alkyl, etc.; or NR7R8 = ring ; n = 1 - 6] are prepd. The title compd. II (NMR data given) in vitro showed IC50 of 6 .mu.M against the release of serotonin from RBL-2H3 cells. II also inhibited the release of arachidonic acid from RBL-2H3 cells.

IT **175281-33-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of acridone derivs. as allergy inhibitors)

RN 175281-33-1 CAPLUS

CN 9(10H)-Acridinone, 3,4-dimethyl-10-[3-(phenylamino)propyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 29 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:171798 CAPLUS
DOCUMENT NUMBER: 124:232479
TITLE: Preparation of pyrimidine derivatives as gastrointestinal movement accelerators
INVENTOR(S): Kikuchi, Haruhiko; Satoh, Hiroaki; Fukutomi, Ruta; Inomata, Kohei; Suzuki, Masashi; Hagihara, Koichiro; Arai, Takeo; Mino, Setsuko; Eguchi, Haruko
PATENT ASSIGNEE(S): Nisshin Flour Milling Co., Ltd., Japan
SOURCE: PCT Int. Appl., 196 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

09/ 995,177

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9531442	A1	19951123	WO 1995-JP937	19950517
W: BR, CA, JP, KR, US				
RW: BE, CH, DE, ES, FR, GB, IT, NL, SE				
CA 2189963	AA	19951123	CA 1995-2189963	19950517
EP 760368	A1	19970305	EP 1995-918728	19950517
EP 760368	B1	19990728		
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
BR 9507666	A	19970923	BR 1995-7666	19950517
ES 2136291	T3	19991116	ES 1995-918728	19950517
US 5736550	A	19980407	US 1996-737335	19961115

PRIORITY APPLN. INFO.: JP 1994-127161 19940518
WO 1995-JP937 19950517

OTHER SOURCE(S): MARPAT 124:232479
GI



AB The title compds. I [X represents O or NR5, and Y represents O, S or NR5, R5 being hydrogen, C1-C6 alkyl, etc.; R1 and R2 represents each independently hydrogen, C1-C6 alkyl, etc.; R3 represents CN or COOR6, R6 being C1-C6 alkyl, C3-C6 cycloalkyl, aryl, etc.; and R4 represents SR7 or NR8R9, wherein R7 represents C1-C6 alkyl, R8 represents C1-C6 alkyl, etc., and R9 represents hydrogen, C1-C6 alkyl, etc., or R8 and R9 together with the nitrogen atom to which they are bonded represent an N-substituted piperazine ring] are claimed. In an in vitro test using elec. stimulated guinea pig ileum, the title compd. II (prepn. given) at 10-7 M promoted acetylcholine release.

IT **174559-32-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of pyrimidine derivs. as gastrointestinal movement accelerators)

RN 174559-32-1 CAPLUS

CN 5-Pyrimidinecarbonitrile, 6-[[9-[3-(4-fluorophenoxy)propyl]-3-oxa-9-azabicyclo[3.3.1]non-7-yl]amino]-1,2,3,4-tetrahydro-4-imino-1,3-dimethyl-2-thioxo-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 30 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:167579 CAPLUS
DOCUMENT NUMBER: 124:202043
TITLE: Preparation of quinolinecarboxylic acid 8-azabicyclo[3.2.1]oct-3-yl ester or amide derivatives as agonists of serotonin receptor 4
INVENTOR(S): Ohuchi, Yutaka; Suzuki, Masaji; Asanuma, Hajime; Yokomori, Sadakazu; Hatayama, Katsuo
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9531455	A1	19951123	WO 1995-JP954	19950518
W: AU, CA, KR, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 08034784	A2	19960206	JP 1995-118794	19950517
AU 9524548	A1	19951205	AU 1995-24548	19950518
AU 685632	B2	19980122		
EP 710662	A1	19960508	EP 1995-918742	19950518
EP 710662	B1	20010404		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
EP 1018513	A2	20000712	EP 1999-123695	19950518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 200286	E	20010415	AT 1995-918742	19950518
US 5753673	A	19980519	US 1996-578532	19960118

PRIORITY APPLN. INFO.: JP 1994-103177 A 19940518
EP 1995-918742 A3 19950518
WO 1995-JP954 W 19950518
OTHER SOURCE(S): MARPAT 124:202043
GI



I

AB The title compds. (I; X = O, NH; m = 0-6; A = alkenyl, alkynyl, haloalkyl, OH, alkoxy, acyloxy, alkoxyalkoxy, mono- or dialkylamino,alkylthio alkylsulfinyl, alkylsulfonyl, arylsulfonyl, aryloxy, morpholinyl, piperidinyl, tetrahydropyranyl, alkoxycarbonyl, CO2H, alkanoyl, cyano, CONH2) or a medicinally acceptable salt thereof, each having a serotoninergic receptor-stimulating effect on serotonin 4 receptors, are prepd. These compds. have the effect of activating digestive tract motion and are efficacious in ameliorating chronic gastritis, diabetes and various diseases accompanying the lowering of stomach motility and gastric excretory function after gastrectomy, such as heartburn anorexia, epigastralgia and abdominal swelling, and in treating reflux esophagitis, false ileus and constipation. Thus, a soln. of 1-isopropyl-2-oxo-1,2-dihydro-3-quinolinecarboxylic acid in SOCl2 was refluxed for 2 h and after distg. off the excess SOCl2, the resulting acid chloride was treated with benzene, followed by adding dropwise a soln. of endo-3-amino-8-methyl-8-azabicyclo[3.2.1]octane in benzene under ice-cooling, and the resulting mixt. was stirred at room temp. for 2 h to give the intermediate I (X = NH, m = 0, A = Me). A soln. of the latter compd. and 1-chloroethyl chloroformate in 1,2-dichloroethane was refluxed for 1 h and after removing the solvent in vacuo, treated with MeOH and heated with stirring to give the precursor I.HCl (X = NH, m = 0, A = H), which was stirred with 3-bromopropene and K2CO3 in EtOH to give the title compd. I (X = NH, m = 0, A = 2-propenyl). In a 5-HT4 receptor-stimulating assay, the title compds. in vitro I showed ED50 of 11.5-73.7 nM for enhancing the elec. stimulation-induced contraction of guinea pig's ileum.

IT **174486-49-8P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of quinolinecarboxylic acid azabicyclooctyl ester or amide derivs. as agonists of serotonin receptor 4 (5-HT4))

RN 174486-49-8 CAPLUS

CN 3-Quinolinecarboxamide, 1,2-dihydro-1-(1-methylethyl)-2-oxo-N-[(3-endo)-8-[2-(phenylsulfonyl)ethyl]-8-azabicyclo[3.2.1]oct-3-yl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 31 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:163902 CAPLUS
DOCUMENT NUMBER: 124:202286
TITLE: Preparation and formulation of morpholine derivatives and analogs as acetylcholine secretion promoters
INVENTOR(S): Kikuchi, Haruhiko; Satoh, Hiroaki; Fukutomi, Ruta; Inomata, Kohei; Suzuki, Masashi; Hagihara, Koichiro; Arai, Takeo; Mino, Setsuko; Eguchi, Haruko
PATENT ASSIGNEE(S): Nisshin flour milling co., ltd., Japan
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9531431	A1	19951123	WO 1995-JP938	19950517
W: BR, CA, JP, KR, US				
RW: BE, CH, DE, ES, FR, GB, IT, NL, SE				
CA 2189964	AA	19951123	CA 1995-2189964	19950517
EP 760362	A1	19970305	EP 1995-918729	19950517
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
BR 9507892	A	19971118	BR 1995-7892	19950517
US 5753654	A	19980519	US 1996-737133	19961107
PRIORITY APPLN. INFO.:			JP 1994-103570	19940518
			WO 1995-JP938	19950517

OTHER SOURCE(S): MARPAT 124:202286
GI



AB The title compds. R1NHC(:X)NR2R3 [R1 = H, alkyl, etc.; R2 = Q1, etc.; R = alkyl, etc.; Z = O, etc.; R3 = H, alkyl, etc.] are claimed. The title compds. are useful for the treatment of diseases of the digestive tract. In an in vitro test using ileum fragment, the title compd. I (prepn. given) at 10-7 M showed acetylcholine secretion promoting activity.
IT **174458-38-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of morpholine derivs. and analogs as acetylcholine secretion promoters)

RN 174458-38-9 CAPLUS

CN Propanedinitrile, [[[9-[3-(4-fluorophenoxy)propyl]-3-oxa-9-azabicyclo[3.3.1]non-7-yl]amino](methylamino)methylene]-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L7 ANSWER 32 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:52859 CAPLUS

DOCUMENT NUMBER: 124:261059

TITLE: Pyridazine derivatives useful as ligands of muscarinic cholinergic receptors

INVENTOR(S): Boigegrain, Robert; Brodin, Roger; Kan, Jean P.; Olliero, Dominique; Bourguignon, Jean Jacques; Worms, Paul

PATENT ASSIGNEE(S): Sanofi, Fr.

SOURCE: U.S., 28 pp. Cont.-in-part of U.S. Ser. No. 737, 654, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5461053	A	19951024	US 1992-964901	19921022
FR 2642754	A1	19900810	FR 1989-1547	19890207
FR 2642754	B1	19910524		
FR 2642757	A1	19900810	FR 1989-1548	19890207
FR 2642757	B1	19910524		
FR 2654727	A1	19910524	FR 1989-15137	19891117
FR 2654727	B1	19920327		
FR 2663326	A2	19911220	FR 1990-7533	19900615
FR 2663326	B2	19921016		
FR 2665442	A1	19920207	FR 1990-9777	19900731
FR 2665442	B1	19921204		
FI 9005663	A	19910518	FI 1990-5663	19901115
ZA 9009221	A	19910925	ZA 1990-9221	19901116
US 5631255	A	19970520	US 1995-473582	19950607
US 5656631	A	19970812	US 1995-473580	19950607

PRIORITY APPLN. INFO.:

FR 1989-1547	19890207
FR 1989-1548	19890207
FR 1989-15137	19891117
US 1990-475489	19900207
FR 1990-7533	19900615
FR 1990-9777	19900731
US 1990-615373	19901119
US 1991-737654	19910730

US 1992-871505 19920421
US 1992-964901 19921022

OTHER SOURCE(S): MARPAT 124:261059

GI



I

AB The present invention relates to pyridazine derivs. I in which: Ar represents a Ph group substituted by R1 and R2 ; R1 and R2 each independently denotes hydrogen, halogen, trifluoromethyl, hydroxyl, C1-C4 alkoxy or C1-C4 alkyl; R3 represents C3H7, C3-C7 cycloalkyl or the Ar' radical, Ar' being Ph substituted by R1 and R2 ; R4 represents the group CH2C(CH2X1)2(CH2)nNR5R6 in which: X1 represents hydrogen or methyl; n is 0; R5 represents a C1-C6 linear alkyl group; and R6 represents a C1-C6 linear alkyl group; or a group Alk-NR5aR6a in which Alk is a C1-C6 linear alkylene group, R5a is hydrogen or a C1-C6 alkyl group and R6a alkyl group, a benzyl or a C3-C7 cycloalkyl, with the proviso that R1 and R2 are not simultaneously H when Alk is (CH2)2, and that R4 is the group AlkNR5aR6a only when R3 is a C3H7 or a Ph group; or its salts, which are pharmaceutically acceptable or permit suitable sepn. or crystn. thereof, which are useful as ligands of cholinergic receptors, in particular, receptors of the M1 type. Thus, e.g., amination of 6-chloro-3-phenyl-4-propylpyridazine (prepn. given) with 2-(dimethylamino)-2-methylpropylamine (prepn. given) afforded a base which was converted to 3-(2-diethylamino-2-methylpropyl)amino-6-phenyl-5-propyl-pyridazine sesquifumarate (SR 46559A); SR 46559A exhibited IC50's of 0.11 and 2.2 .mu.mol, resp., representing affinity for M1 and M2 muscarinic cholinergic receptors. Pharmaceutical formulations were given.

IT **141234-88-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(pyridazine derivs. useful as ligands of muscarinic cholinergic receptors)

RN 141234-88-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-ethanamine, N-(6-methyl-5-phenyl-3-pyridazinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 141823-70-3
CMF C20 H26 N4



09/ 995,177

CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L7 ANSWER 33 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:899332 CAPLUS
DOCUMENT NUMBER: 124:24916
TITLE: First Example of a 99mTc Complex as a Dopamine Transporter Imaging Agent
AUTHOR(S): Meegalla, Sanath; Ploessl, Karl; Kung, Mei-Ping; Stevenson, D. Andrew; Liable-Sands, Louise M.; Rheingold, Arnold L.; Kung, Hank F.
CORPORATE SOURCE: Department of Radiology, University of Pennsylvania, Philadelphia, PA, 19104, USA
SOURCE: J. Am. Chem. Soc. (1995), 117(44), 11037-8
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A Tc-99m labeled cocaine analog that is potentially useful for in vivo imaging of dopamine transporters is demonstrated. A novel N-ethanethiol tropane deriv. contg. a neutral heterodimeric TcVO aminobisethanethiol and a monothiol complex moiety (Technetium, [methyl 3-(4-chlorophenyl)-8-(2-mercaptoethyl)-8-azabicyclo[3.2.1]octane-2-carboxylato-S][2,2'-(methylimino)bis[ethanethiolato]](2-)-N,S,S'oxo), [99mTc]-4, was prepd. in high purity. In vivo biodistribution of [99mTc]-4 after an i.v. injection showed specific uptake in the striatum of male Sprague-Dawley rats. X-ray crystallog. of a similar rhenium complex, Re-4, displayed an expected structure, with a pyramidal Re:O core and a N-Me group at the anti position to the Re:O functionality. In vitro binding in rat striatal membrane homogenates, using a comparable compd., [125I]IPT, as the ligand, showed an excellent binding affinity. The inhibition const. (Ki) of Re-4 was 0.31 .+-. 0.03 nM ([125I]-IPT Kd = 0.2 nM). This is the first example of a Tc-99m complex that displays selective dopamine transporter binding. Further studies are warranted to fully characterize this series of new Tc-99m complexes that may be very important as a tool for early detection of Parkinson's disease.

IT **171296-11-0P**
RL: BPR (Biological process); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PROC (Process)
(99mTc-cocaine analog complex for imaging of dopamine transporter in brain for Parkinson's disease diagnosis)

RN 171296-11-0 CAPLUS
CN Rhenium, [methyl 3-(4-chlorophenyl)-8-(2-mercaptoethyl)-8-azabicyclo[3.2.1]octane-2-carboxylato-S][[2,2'-(methylimino)bis[ethanethiolato]](2-)-N,S,S']oxo-, stereoisomer (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A





L7 ANSWER 34 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:673200 CAPLUS
DOCUMENT NUMBER: 123:160059
TITLE: SR 46559A, an atypical muscarinic compound with no cholinergic syndrome: chemical approach and pharmacological profile
AUTHOR(S): Boigegrain, Robert; Kan, Jean-Paul; Olliero, Dominique; Brodin, Roger; Soubrie, Philippe; Bourguignon, Jean-Jacques; Wermuth, Camille-Georges
CORPORATE SOURCE: Sanofi Recherche 371, Montpellier, 34184, Fr.
SOURCE: Eur. J. Med. Chem. (1995), 30(Suppl., Proceedings of the 13th International Symposium on Medicinal Chemistry, 1994), 175s-85s
CODEN: EJMCA5; ISSN: 0223-5234
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Chem. modifications of the skeleton of minaprine provided 2 series of pyridazine derivs. with muscarinic M1 receptor affinities varying from 1 .times. 10-7 M to 3 .times. 10-9 M. SR 46559A (which was prepd.) appears to be a potent M1 muscarinic agonist, devoid of any cholinergic symptoms

and with a marked ability to improve exptl.-induced cognitive/memory deficits in rodents. These data suggest that this compd. could be useful in the treatment of dementia, esp. when cholinergic hypofunction is implicated (e.g. Alzheimer's disease).

IT **146824-64-8**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); **BIOL (Biological study)**; **BIOL (Biological study)**; PROC (Process)
(SR 46559A as atypical muscarinic compd. with no cholinergic syndrome cognition-enhancing activity and minaprine analogs interaction with M1 muscarinic receptors)

RN 146824-64-8 CAPLUS
CN Phenol, 2-[6-[[2-(8-azabicyclo[3.2.1]oct-8-yl)ethyl]amino]-4-methyl-3-pyridazinyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 35 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:570765 CAPLUS
DOCUMENT NUMBER: 122:314571
TITLE: Preparation of substituted heterocycle compounds enhancing antitumor activity of other cytotoxic agents
INVENTOR(S): Arnold, Lee D.; Coe, Jotham W.; Kaneko, Takushi; Moyer, Mikel P.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9422846	A1	19941013	WO 1994-US1724	19940228
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FI 9401452	A	19941001	FI 1994-1452	19940329

PRIORITY APPLN. INFO.: US 1993-40233 19930330
OTHER SOURCE(S): MARPAT 122:314571
GI



I

AB Title compds. R100R101R102N (R100 = Q1A1B1Y2(CH2)mCH(Z1)Y1, Q1O(CH2)2C(OH)(R103)CH2, substituted cycloalkyl, etc., wherein R103 = C1-4 alkyl, Y1 = O, H2C, (CH2)2, bond; Z1 = H, HO, F3C, O2N, C1-4 alkoxy; Y2 = O, S, HN, MeN, bond, CONH, NHCO; B1 = bond, substituted Ph; A1 = bond, C1-4 alkylene, O, S, HN; Q1 = (substituted) heterocyclyl, (substituted) aryl; R100, R101 = H, C1-4 alkyl, C2-4 alkenyl-Ph, C1-4 alkyl-substituted Ph; R102 = H, (substituted)aryl, (substituted)heterocyclyl, etc.) and a salt thereof, useful for inhibiting P-glycoprotein in a mammal and as anticancer agents (no data), are prepd. 2-Methyl-7-(2-oxiranylmethoxy)benzothiazole and 1-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine were refluxed to give the title compd. I.

IT **163298-24-6P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of substituted heterocycle compds. enhancing antitumor activity of other cytotoxic agents)

RN 163298-24-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octan-3-one, 8-[2-hydroxy-3-(4-quinolinyloxy)propyl]-2,4-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 36 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:106994 CAPLUS

DOCUMENT NUMBER: 120:106994

TITLE: Preparation of heteroaryl-8-azabicyclo(3.2.1)octanes as antipsychotic agents, 5-HT3 receptor antagonists and inhibitors of the reuptake of serotonin

INVENTOR(S): Glamkowski, Edward J.; Fink, David M.; Kurys, Barbara E.; Chiang, Yulin

PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals Inc., USA

09/ 995,177 .

SOURCE: U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 650,144, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5234931	A	19930810	US 1992-831027	19920204
FI 9200435	A	19920805	FI 1992-435	19920131
CA 2060573	AA	19920805	CA 1992-2060573	19920203
NO 9200438	A	19920805	NO 1992-438	19920203
AU 9210605	A1	19920806	AU 1992-10605	19920203
AU 641842	B2	19930930		
HU 60494	A2	19920928	HU 1992-321	19920203
HU 207863	B	19930628		
ZA 9200753	A	19921028	ZA 1992-753	19920203
JP 05059049	A2	19930309	JP 1992-17668	19920203
JP 08009613	B4	19960131		
HU 62295	A2	19930428	HU 1992-3977	19920203
HU 217616	B	20000328		
PL 169092	B1	19960531	PL 1992-293363	19920203
AT 138377	E	19960615	AT 1992-101706	19920203
ES 2089255	T3	19961001	ES 1992-101706	19920203
IL 100861	A1	19970218	IL 1992-100861	19920203
RU 2075479	C1	19970320	RU 1992-5010691	19920203
CZ 284754	B6	19990217	CZ 1992-297	19920203
US 5334599	A	19940802	US 1993-37134	19930325
US 5340936	A	19940823	US 1993-37047	19930325

PRIORITY APPLN. INFO.: US 1991-650144 B2 19910204
HU 1992-321 A3 19920203
US 1992-831027 A3 19920204

OTHER SOURCE(S): MARPAT 120:106994
GI



I

AB Title compds. I (X = O, S; Y = H, halo, alkoxy; p, m = 1,2; n = 2-4; R = H, halo, alkyl, alkoxy, HO, halo, H2N, alkylamino, O2N, alkylthio, F3CO, NC, F3C, alkylcarbonyl, (substituted) arylcarbonyl) or a salt, geometric or optical isomers thereof, showing the effects described in the title, are prepd. Di-Et 1-(2-fluorophenyl)-1-methoxymethanephosphonate (prepn. given) in THF was treated with BuLi and tropinone to give (2-fluorophenyl)(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)methanone-HCl which was converted in 4 steps to give I (X = O, Rm = 3,4-(MeO)Ac, Yp = H, n = 4).HCl (II). In an assay for potential antidepressant activity which block serotonin uptake the IC50 of II was 0.027 .mu.M.

IT **144062-09-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**;

PREP (Preparation); USES (Uses)
(prepn. of, as drug)
RN 144062-09-9 CAPLUS
CN Ethanone, 1-[4-[4-[3-(1,2-benzisoxazol-3-yl)-8-azabicyclo[3.2.1]oct-8-yl]butoxy]-3-methoxyphenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 37 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1992:235646 CAPLUS
DOCUMENT NUMBER: 116:235646
TITLE: Preparation of 3-aminopyridazines as psychoanaleptic agents
INVENTOR(S): Boigegrain, Robert; Brodin, Roger; Kan, Jean Paul; Olliero, Dominique; Wermuth, Camille Georges
PATENT ASSIGNEE(S): SANOFI S. A., Fr.
SOURCE: Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 469992	A1	19920205	EP 1991-402145	19910730
EP 469992	B1	19940921		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2665442	A1	19920207	FR 1990-9777	19900731
FR 2665442	B1	19921204		
CA 2048162	AA	19920201	CA 1991-2048162	19910730
NO 9102972	A	19920203	NO 1991-2972	19910730
NO 179905	B	19960930		
NO 179905	C	19970108		
IL 99013	A1	19960119	IL 1991-99013	19910730
FI 9103656	A	19920201	FI 1991-3656	19910731
AU 9181476	A1	19920206	AU 1991-81476	19910731
AU 638858	B2	19930708		
HU 58706	A2	19920330	HU 1991-2555	19910731
HU 213392	B	19970630		
ZA 9106030	A	19920429	ZA 1991-6030	19910731
JP 04234369	A2	19920824	JP 1991-213203	19910731

PRIORITY APPLN. INFO.: FR 1990-9777 19900731
OTHER SOURCE(S): MARPAT 116:235646
GI



I



II

AB Title compds. [I; R = (substituted) Ph; R3 = alkyl, CH2Ph, CH2CH2Ph; R4 = aminoalkyl, heterocyclylalkyl, etc.] were prepd. Thus, 4-FC6H4CH2COPr (prepn. given) was condensed with BrCH2CO2Et and the product cyclocondensed with H2NNH2 to give, in 2 addnl. steps, phenylpyridazine II (R8 = F, R9 = Cl). The latter was condensed with H2NCH2CMe2NEt2 to give II (R8 = F, R9 = NHCH2CMe2NEt2]. II [R8 = Cl, R9 = NH(CH2)3NEt2] had ED50 of 0.47 mg/kg orally for inhibition of pirenzepine-induced amnesia in rats.

IT **141234-88-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of, as psychoanaleptic agent)

RN 141234-88-0 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-ethanamine, N-(6-methyl-5-phenyl-3-pyridazinyl)-, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 141823-70-3
CMF C20 H26 N4



CM 2

CRN 110-17-8
CMF C4 H4 O4
CDES 2:E

Double bond geometry as shown.



L7 ANSWER 38 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1990:158030 CAPLUS
DOCUMENT NUMBER: 112:158030
TITLE: Studies on substituted 9-azabicyclo[3.3.1]nonan-3-ones

09/ 995,177

AUTHOR(S): Rao, J.; Saxena, Anil K.
CORPORATE SOURCE: Med. Chem. Div., CDRI, Lucknow, 226 001, India
SOURCE: Indian J. Chem., Sect. B (1989), 28B(8), 620-5
CODEN: IJSBDB; ISSN: 0376-4699
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:158030
GI



I



II

AB 9-Azabicyclo[3.3.1]nonan-3-ones I (X = CO, R = F; X = S, R = H, Cl, NO2, NHAc, OMe, Me) were prepd. by condensation of 9-azabicyclo[3.3.1]nonan-3-one with the appropriate chlorosulfide or phenone. Prepn. of 9-azabicyclo[3.3.1]nonan-3,7-dione II was also achieved. I (X = CO, R = F) had antihypotensive antibody, and I (X = S, R = Cl, OMe), antiinflammatory activity.

IT **125835-00-9P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation)
(prepn. and antiinflammatory activity of)
RN 125835-00-9 CAPLUS
CN 9-Azabicyclo[3.3.1]nonan-3-one, 9-[3-[(4-chlorophenyl)thio]propyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 39 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1989:567138 CAPLUS
DOCUMENT NUMBER: 111:167138
TITLE: Synthesis and anesthetic activity of acetomesidides containing tropane and piperidine fragments
AUTHOR(S): Kostochka, L. M.; Mochalovskii, S. E.; Chernyakova, I. V.; Skoldinov, A. P.; Zhukov, V. N.
CORPORATE SOURCE: NII Farmakol., Moscow, USSR
SOURCE: Khim.-Farm. Zh. (1989), 23(6), 684-6
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 111:167138
GI



I

AB Acetomesidides (I, NR2 = tropane or piperidine deriv.) were prepd. by the amination of chloroacetomesidide with corresponding amines. Among the compds. studied, tropane derivs. showed greater anesthetic activity than piperidine derivs. as detd. in mice. Nortropidinoacetomesidide and nortropinoacetomesidide showed the greatest activity.

IT **93990-42-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. and anesthetic activity of)

RN 93990-42-2 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-8-acetamide, 3-hydroxy-N-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 40 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:164608 CAPLUS

DOCUMENT NUMBER: 108:164608

TITLE: New antiparasitic agents. III. Comparison between trypanocidal activities of some acridine derivatives against Trypanosoma cruzi in vitro

AUTHOR(S): Osuna, Antonio; Ruiz-Perez, Luis Miguel; Gamarro, Francisco; Rodriguez-Santiago, Juan Ignacio; Castanys, Santiago; Sharples, Derek; Galy, Anne Marie; Giovannangeli, Genevieve; Galy, Jean Pierre; et al.

CORPORATE SOURCE: Fac. Farm., Univ. Granada, Granada, Spain

SOURCE: Chemotherapy (Basel) (1988), 34(2), 127-33
CODEN: CHTHBK; ISSN: 0009-3157

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Some acridine compds. (9-imino, 9-oxo and 9-thio derivs.) were screened for activity against T. cruzi in vitro. The results are discussed with ref. to the structure of the compds. Attempts to elucidate the mode of action of the active acridines are also included. The most active compds. were 9-thioacridanones and 9-thio-1,2,3,4-tetrahydroacridanones. The dialkylaminoalkylthio group seemed to be the most suitable mol. moiety for trypanocidal activity in the 9-substituted acridine series.

IT **73302-60-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation)
(prepn. and trypanocidal activity of, structure in relation to)

RN 73302-60-0 CAPLUS

CN 9(10H)-Acridinone, 10-(3-phenoxypropyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 41 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1987:99213 CAPLUS
DOCUMENT NUMBER: 106:99213
TITLE: Antiamebic activity of new acridine derivatives against Naegleria and Acanthamoeba species in vitro
AUTHOR(S): Osuna, Antonio; Rodriguez-Santiago, Juan Ignacio; Ruiz-Perez, Luis Miguel; Gamarro, Francisco; Castanys, Santiago; Giovannangeli, Genevieve; Galy, Anne Marie; Galy, Jean Pierre; Soyfer, Jean Claude; Barbe, Jacques
CORPORATE SOURCE: Fac. Farm., Univ. Granada, Granada, Spain
SOURCE: Chemotherapy (Basel) (1987), 33(1), 18-21
CODEN: CHTHBK; ISSN: 0009-3157
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In vitro antiamebic activity of selected acridine derivs. has been investigated against Naegleria and Acanthamoeba species. The most active compds. belong to the 9-thioacridanone and the 1,2,3,4-tetrahydro-9-thioacridanone series. In addn., some structure-activity relationships are proposed.

IT **73302-60-0**
RL: BAC (Biological activity or effector, except adverse); **BIOL (Biological study)**
(antiamebic activity of, structure in relation to)
RN 73302-60-0 CAPLUS
CN 9(10H)-Acridinone, 10-(3-phenoxypropyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 42 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1985:515949 CAPLUS
DOCUMENT NUMBER: 103:115949
TITLE: Alkaloid cardenolides
AUTHOR(S): Makarevich, I. F.; Ivanov, L. V.; Khadzhai, Ya. I.; Belokon, V. F.; Pavlova, V. V.; Klimenko, O. I.; Bondar, N. I.; Uryupina, E. V.
CORPORATE SOURCE: Vses. Nauchno-Issled. Inst. Khim. Tekhnol. Lek. Sredstv, Kharkov, USSR
SOURCE: Khim. Prir. Soedin. (1985), (2), 239-44
CODEN: KPSUAR; ISSN: 0023-1150
DOCUMENT TYPE: Journal
LANGUAGE: Russian

GI



I

AB Eight alkaloid cardenolides were prepd. by previously published methods and tested for antiarrhythmic activity in rats. One of the most active of these compds., strophanthidin-3.beta.-O-acetyl-2'-N(b)ajmaline chloride (I) [83059-99-8], increased the survival rate of rats with CaCl2-induced arrhythmias from 20 to 43% when administered at 0.1 mg/kg. The i.p. LD50 of I was 130 mg/kg. Two of the very active cardenolides showed even lower toxicity than I.

IT **67205-13-4P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. and antiarrhythmic activity of)

RN 67205-13-4 CAPLUS

CN Ajmalanium, 4-[2-[[(3.beta.,5.beta.,14.beta.)-21,23-epoxy-5,14-dihydroxy-19,23-dioxo-24-norchol-20(22)-en-3-yl]oxy]-2-oxoethyl]-17,21-dihydroxy-, bromide, (17R,21.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 2-A



● Br^-

L7 ANSWER 43 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1985:6888 CAPLUS
DOCUMENT NUMBER:	102:6888
TITLE:	Synthesis and biological activity of quaternary derivatives of tropine alkaloids. I. Tropine derivatives
AUTHOR(S):	Gorecki, P.; Drozdzynska, M.; Kedzia, B.; Przybylska, D.
CORPORATE SOURCE:	Inst. Przem. Zielarskiego, Poznan, 61-707, Pol.
SOURCE:	Herba Pol. (1983), 29(2), 135-49 CODEN: HPBIA9; ISSN: 0018-0599
DOCUMENT TYPE:	Journal
LANGUAGE:	Polish
GI	



I

AB Alkylation of tropine with 2-chloroacetanilides gave the quaternary salts I (R = EtO, EtO2C, H2NSO2) which had, e.g., antihypertensive, antiulcer, and bactericidal activity.

IT **93614-57-4P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation)
(prepn. and biol. activity of)

RN 93614-57-4 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 8-[2-[(4-ethoxyphenyl)amino]-2-oxoethyl]-3-hydroxy-8-methyl-, chloride, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Cl -

L7 ANSWER 44 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1984:483846 CAPLUS

DOCUMENT NUMBER: 101:83846

TITLE: Pharmacological studies of bisatropinium bromide, a new muscle relaxant

AUTHOR(S): Chen, Genkang; Fang, Ruiying; Zhang, Yuanpei

CORPORATE SOURCE: Fac. Pharm. Sci., Zhejiang Med. Univ., Hangzhou, Peop. Rep. China

SOURCE: Yaoxue Xuebao (1984), 19(1), 21-7
CODEN: YHHPAL; ISSN: 0513-4870

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

GI



I

AB Animal expts. showed (1,4-diethoxybenzene)bisatropinium dibromide (I) [91318-09-1] to be a muscle relaxant of high potency, suitable duration of action, and relative safety, suggesting potential clin. use. I was a nondepolarizing type of muscle relaxant and had feeble antimuscarinic activity.

IT **91318-09-1**
RL: BAC (Biological activity or effector, except adverse); **BIOL (Biological study)**
(muscle-relaxant activity of)

RN 91318-09-1 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 8,8'-[1,4-phenylenebis(oxy-2,1-ethanediyl)]bis[3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-, dibromide (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 45 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1980:129153 CAPLUS
DOCUMENT NUMBER: 92:129153
TITLE: Cardenolide and bufadienolide derivatives of ajmaline
AUTHOR(S): Makarevich, I. F.; Khadzhai, Ya. I.; Nikolaeva, A. V.; Pavlova, V. V.
CORPORATE SOURCE: Khar'k. Nauchno-Issled. Khim.-Farm. Inst., Kharkov, USSR
SOURCE: Khim. Prir. Soedin. (1979), (4), 537-40
CODEN: KPSUAR; ISSN: 0023-1150
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



I



II

AB Title compds. I and II were prepd. by condensation of ajmaline with 3-O-(bromoacetyl)strophanthidin and 3-O-(bromoacetyl)hellebrigenin. Antiarrhythmic activity of I was not accompanied by an increase in blood pressure.

IT **67205-13-4P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. and antiarrhythmic activity of)

RN 67205-13-4 CAPLUS

CN Ajmalanium, 4-[2-[[(3.beta.,5.beta.,14.beta.)-21,23-epoxy-5,14-dihydroxy-19,23-dioxo-24-norchol-20(22)-en-3-yl]oxy]-2-oxoethyl]-17,21-dihydroxy-, bromide, (17R,21.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

PAGE 1-A



PAGE 2-A



● Br^-

L7 ANSWER 46 OF 47 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1976:144582 CAPLUS
DOCUMENT NUMBER: 84:144582
TITLE: Structure-activity relations in various 4-substituted ajmaline derivatives
AUTHOR(S): Femmer, Klaus; Gabsch, G.; Braun, K.
CORPORATE SOURCE: Direktionsber. Forsch., VEB Arzneimittelwerk Dresden, Radebeul, E. Ger.
SOURCE: Pharmazie (1976), 31(1), 36-9
CODEN: PHARAT
DOCUMENT TYPE: Journal
LANGUAGE: German
GI

09/ 995,177



I

AB Twenty-one 4-substituted ajmalines (I), 14 4-substituted 21-dihydroajmalines, 13 4-substituted 21-deoxydihydroajmalines, 10 4-substituted 21-deoxydihydroisoajmalines, 5 4-substituted 21-deoxydihydroajmalones, and 7 4-substituted 21-deoxyajmalines were testd for antiarrhythmic effects in the aconitine test and for toxicity in rats. The ajmaline series had the greatest antiarrhythmic effectiveness followed by the 21-deoxydihydroajmaline, 21-deoxydihydroisoajmaline, and 21-dihydroajmaline series. Compds. of the 21-deoxydihydroajmalone and 21-deoxyajmaline series were generally inactive. Compds. of the 4 active series contg. .beta.-diethylaminoethyl, .beta.-piperidinoethyl, 3'-diethylamino-2'-hydroxypropyl, 3'-piperidino-2'-hydroxypropyl, 3'-morpholino-2'-hydroxypropyl, and 3'-pyrrolidino-2'-hydroxypropyl substituents were the most active. The LD50:ED20 (20% effective dose) ratios for the 14 most active compds. ranged from 7.9 to 23.2.

IT **58892-94-7**
RL: **BIOL (Biological study)**
(heart arrhythmia response to)

RN 58892-94-7 CAPLUS

CN Ajmalanium, 17,21-dihydroxy-4-[2-hydroxy-3-(3-methylphenoxy)propyl]-, (17R,21.alpha.)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 47 OF 47 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1968:103723 CAPLUS

DOCUMENT NUMBER: 68:103723

TITLE: Curariform activity of diplacin analogs

AUTHOR(S): Medvedev, B. A.; Mashkovskii, M. D.

CORPORATE SOURCE: Vses. Nauch.-Issled. Khim.-Farm. Inst. im. Ordzhonikidze, Moscow, USSR

SOURCE: Farmakol. Toksikol. (Moscow) (1968), 31(1), 34-6
CODEN: FATOAO

DOCUMENT TYPE: Journal

09/ 995,177

LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB Expts. on anesthetized cats showed that substitution of a 3-benzylquinuclidine moiety (A) or 3,9-diazabicyclo[3.3.1]nonane moiety (B or C) heterocycle for the platinecin ring of the diplacin mol. decreased its curariform activity. In rabbits, the activity of diplacin 3-benzylquinuclidine analog, 1,3-(RCH2CH2O)2C6H4.2X- (I, R = A, X = Br-) was not significantly different from that of diplacin itself, but both diplacin diazabicyclononane analogs, I (R = B, X = Br-) and I (R = C, X = I-) (II), were less effective than the parent compd. in blocking neuromuscular cond. These substitutions did not alter the mechanism of curariform action. In addn. to its curariform properties, II had anticholinesterase activity.
IT **16405-22-4**
RL: BAC (Biological activity or effector, except adverse); **BIOL (Biological study)**
(curariform activity of)
RN 16405-22-4 CAPLUS
CN 3-Aza-9-azoniabicyclo[3.3.1]nonane, 9,9'-[1,3-phenylenebis(oxy-2,1-ethanediyl)]bis[3,9-dimethyl-, dibromide (9CI) (CA INDEX NAME)





●2 Br⁻

=> d his

(FILE 'HOME' ENTERED AT 15:49:06 ON 09 MAY 2002)

FILE 'REGISTRY' ENTERED AT 15:49:14 ON 09 MAY 2002
L1 STRUCTURE UPLOADED
L2 4 S L1
L3 742 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:50:11 ON 09 MAY 2002
L4 140 S L3
L5 6 S L4 AND PROPION?
L6 50 S L3/BIOL
L7 47 S L6 NOT L5

=> log y
COST IN U.S. DOLLARS SINCE FILE TOTAL

09/ 995,177

	ENTRY	SESSION
FULL ESTIMATED COST	237.31	378.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-32.83	-32.83

STN INTERNATIONAL LOGOFF AT 15:55:02 ON 09 MAY 2002